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Chemotherapy  remains  the  only  available  treatment  for  triple-­‐‑negative  (TN)  breast  
cancer.  Although  some  TN  breast  cancers  respond  initially  to  neoadjuvant  
chemotherapy,  the  majority  of  patients  die  within  three  years  of  treatment  due  to  
recurrent  tumor  growth.  Developing  ex  vivo  models  for  TN  breast  cancer  recurrence  and  
defining  responsible  molecules  will  be  crucial  to  developing  effective  combination  
therapies  for  TN  breast  cancer  patients.  We  have  developed  an  in  vitro  model  of  TN  
breast  cancer  dormancy/recurrence.  Short-­‐‑term  exposure  of  tumor  cells  to  chemotherapy  
at  clinically  relevant  doses  enriches  for  a  dormant  tumor  cell  population.  Several  days  
after  removing  chemotherapy,  dormant  tumor  cells  regain  proliferative  ability  and  
establish  colonies,  resembling  tumor  recurrence.  Tumor  cells  from  “recurrent”  colonies  
exhibit  increased  chemotherapy  resistance,  resembling  therapy  resistance  of  recurrent  
tumors  in  patients.  Furthermore,  we  identify  a  novel  signaling  axis  [nuclear  bFGF/DNA-­‐‑
dependent  protein  kinase  (DNA-­‐‑PK)]  supported  by  chemotherapy-­‐‑enriched  dormant  
TN  breast  cancer  cells.  This  signaling  axis  drives  accelerated  DNA  repair  in  chemo-­‐‑
residual  TN  breast  cancer  cells.  Targeting  this  axis  with  either  with  a  bFGF  shRNA  or  
DNA-­‐‑PK  small  molecule  inhibitor  blocks  recurrent  colony  formation.  Using  the  
Oncomine  gene  expression  database,  we  found  that  bFGF  expression  in  tumor  samples  
from  TN  breast  cancer  patients  predicts  five-­‐‑year  tumor  recurrence  following  
    
v  
neoadjuvant  chemotherapy  treatment.  Finally,  we  demonstrate  that  recurrent  tumor  
cells  exhibit  increased  invasiveness,  reflecting  the  aggressive  behavior  of  recurrent  
tumors  in  patients.  Collectively,  these  studies  identify  a  novel  signaling  axis  in  TN  
breast  cancer  that  likely  contributes  to  tumor  recurrence  and  provide  molecular  targets  
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1. Introduction  
1.1 Triple-negative (TN) breast cancer 
Breast  cancer  has  been  the  most  common  type  of  cancer  in  women  in  the  United  
States  for  many  years.  It  is  estimated  that  approximately  235,030  new  cases  of  breast  
cancer  and  40,430  breast  cancer  deaths  will  occur  in  US  women  in  2014[1].  The  current  
treatment  includes  primary  therapy,  which  is  usually  surgery,  and  adjuvant  and  
neoadjuvant  therapies,  including  chemotherapy,  radiation,  and  targeted  therapy.  By  
interfering  with  specific  molecules  on  tumor  cells,  targeted  therapy,  including  hormonal  
agents  and  Trastuzumab,  has  greatly  prolonged  survival  in  the  past  few  decades.  
However,  targeted  therapy  is  currently  only  available  for  breast  cancers  expressing  
estrogen  receptor  (ER),  progesterone  receptor  (PR),  or  human  epidermal  growth  factor  
receptor  2  (HER2).  Breast  cancers  that  do  not  express  these  receptors  cannot  benefit  from  
this  therapeutic  strategy.  These  tumors  are  often  referred  to  as  triple-­‐‑negative  breast  
cancers.  
Triple-­‐‑negative  (TN)  breast  cancers  are  defined  as  tumors  lacking  expression  of  
ER,  PR,  and  HER2.  They  account  for  approximately  12-­‐‑17%  of  all  breast  cancers  in  
patients[2].  Although  triple-­‐‑negative  breast  cancers  are  very  heterogeneous,  as  a  group  
they  are  often  associated  with  a  worse  prognosis,  compared  with  receptor-­‐‑positive  
breast  cancers.  TN  breast  cancer  is  associated  with  decreased  3-­‐‑year  survival  rate,  higher  
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risk  for  visceral  metastasis,  and  shorter  post-­‐‑recurrence  survival[3].  Patients  with  TN  
breast  cancer  have  an  increased  likelihood  of  recurrence  within  5  years  of  diagnosis[3,  4].  
Besides  the  aggressive  nature  of  TN  breast  cancer,  the  adverse  outcome  is  largely  
due  to  the  lack  of  targeted  therapy.  For  patients  with  TN  breast  cancers,  the  only  
currently  available  systemic  treatment  is  chemotherapy.  Although  there  is  no  
unanimous  regimen  for  all  TN  breast  cancer  patients,  the  commonly  used  agents  are  
doxorubicin,  cyclophosphamide,  and  docetaxel,  given  short  term  for  several  cycles.  
Platinums,  such  as  cisplatin  and  carboplatin,  are  currently  being  evaluated  in  clinical  
trials[2].    
1.2 Tumor dormancy and recurrence 
Despite  receiving  surgery  and  perioperative  systemic  treatment,  patients  with  
TN  breast  cancer  often  develop  recurrent  local  or  metastatic  tumor  with  patency  ranging  
from  years  to  decades.  This  phenomenon  can  be  explained  by  cancer  dormancy:  the  
chemo-­‐‑residual  tumor  cells  remain  inactive  and  patients  are  asymptomatic[5].  The  
underlying  mechanism  of  cancer  dormancy  is  poorly  understood.  Compelling  evidence  
show  that  a  subpopulation  of  chemo-­‐‑resistant  cells  can  survive  from  chemotherapy  and  
enter  a  non-­‐‑proliferative  quiescent  state  for  many  years  before  resuming  growth,  
resulting  in  tumor  recurrence  (Fig.  1).  This  dormant  state  is  alternatively  referred  to  as  
cellular  senescence[6-­‐‑9].  Senescent  cells  can  be  identified  by  increased  β-­‐‑galactosidase,  
upregulation  of  p16,  activation  of  p53,  and  active  metabolism  despite  a  G1  arrest[5].  
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Although  senescence  is  traditionally  considered  irreversible,  post-­‐‑chemotherapy  tumor  
cell  senescence  can  be  reversible,  based  on  the  evidence  that  tumor  samples  from  breast  
cancer  patients  after  chemotherapy  stain  β-­‐‑gal  and  p16  positive[10].  Additionally,  it  has  
been  reported  that  post-­‐‑chemotherapy  senescent  cells  can  overcome  cell  cycle  arrest  at  
low  frequency  and  resume  proliferation  in  vitro[6,  9,  11].  Such  senescent  cell  have  
characteristic  morphologic  features  including  enlarged  and  flattened  shape,  cytoplasmic  
granularity,  and  nuclear  polyploidy[12].    
  
Figure  1:  Model  of  tumor  dormancy  and  recurrence.  Individual  tumor  is  
heterogeneous.  The  original  bulk  of  tumor  contains  chemo-­‐‑sensitive  cells  (blue)  and  
chemo-­‐‑resistant  cells  (red).  Chemotherapy  eliminates  chemo-­‐‑sensitive  tumor  cells  while  
leaving  chemo-­‐‑resistant  cells  intact.  Residual  chemo-­‐‑resistant  cells  remain  dormant  for  a  
period  of  time  before  resuming  growth,  resulting  in  tumor  recurrence.  Recurrent  tumors  
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1.3 Basic fibroblast growth factor (bFGF) 
Basic  fibroblast  growth  factor  (bFGF,  alternative  name:  FGF-­‐‑2),  a  member  of  the  
fibroblast  growth  factor  family,  is  ubiquitously  conserved  in  eukaryotic  organisms.  
Although  its  primary  function  is  stimulating  fibroblast  proliferation,  bFGF  is  a  
multifunctional  cytokine,  regulating  proliferation  and  differentiation  of  many  different  
types  of  cells.    
Human  bFGF  contains  several  isoforms:  the  18  kDa  low  molecular  weight  
(LMW)  isoform  originates  from  translation  at  the  AUG  initiation  codon;  the  high  
molecular  weight  (HMW)  isoforms,  including  22,  22.5,  and  24  kDa,  originate  from  
alternative  translation  at  additional  CUG  initiation  codons  located  on  the  same  mRNA.  
An  additional  34  kDa  isoform  is  also  observed  but  is  often  poorly  translated.  Unlike  the  
LMW  isoform,  the  HMW  isoforms  are  produced  through  an  internal  ribosome  entry  site  
(IRES)  by  CAP-­‐‑independent  translation,  which  is  often  stimulated  during  cellular  stress  
[13].  Besides  the  difference  in  translation  mechanism,  LMW  and  HMW  isoforms  have  
distinctive  subcellular  localization.  The  LMW  isoform  is  predominantly  localized  in  the  
cytosol,  but  is  also  released  into  extracellular  space,  for  paracrine  or  autocrine  (through  
receptor  on  cell  surface)  purpose.  In  contrast,  the  HMW  isoforms  are  mainly  localized  in  
the  nucleus  due  to  nuclear  localization  sequences  (NLS)  (Fig.  2)  [13].  However,  recent  
studies  revealed  that  the  LMW  isoform  can  also  localize  to  the  nucleus  due  to  a  
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nonclassical  NLS  in  the  C-­‐‑terminus[14,  15].  Conversely,  a  small  number  of  HMW  
isoforms  also  present  in  the  cytosol[13].      
A                                                                         
 
B 
       
Figure  2:  Cytosolic  and  nuclear  isoforms  of  bFGF.  A.  Alternative  translation  results  in  
LMW  (18  kDa)  bFGF  and  HMW  (22,  22.5,  24,  and  34  kDa)  bFGF.  Adapted  from  [13]  B.  
Schematic  illustration  of  bFGF  subcellular  localization.  The  LMW  isoform  (red)  is  
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Through  receptor(s)  on  the  cell  surface,  LMW  bFGF  re-­‐‑enters  into  cells  to  form  an  
autocrine  loop.  In  contrast,  the  HMW  isoforms  (blue)  are  produced  in  the  cytoplasm  but  
mainly  localized  in  the  nucleus.  LMW,  low  molecular  weight;  HMW,  high  molecular  
weight.  
  
Cytosolic  and  nuclear  isoforms  of  bFGF  have  similar  and  different  biological  
functions.  Both  of  them  can  induce  angiogenesis,  increase  cardiomyocyte  proliferation,  
and  stimulate  neuronal  regeneration,  although  through  different  signaling  
pathways[13].  However,  only  the  18  kDa  cytosolic  isoform  induces  cell  migration,  but  
not  the  nuclear  isoforms[16].  In  cell  differentiation,  undifferentiated  human  embryonic  
stem  cells  express  both  the  cytosolic  and  nuclear  isoforms  of  bFGF.  However,  after  the  
induction  of  differentiation,  only  the  cytosolic  isoform  is  observed,  indicating  the  role  of  
nuclear  isoforms  in  maintenance  of  pluripotency[17].    
Furthermore,  bFGF  demonstrates  important  functions  in  cancer.  Cytosolic  
(secreted)  isoforms  of  basic  fibroblast  growth  factor  (bFGF)  have  been  implicated  in  
tumor  resistance  to  anti-­‐‑angiogenic  therapy[18-­‐‑23].  It  has  also  been  reported  that  cells  
overexpressing  the  24  kDa  isoform  become  radioprotected  compared  to  the  wild  type  or  
18  kDa  isoform-­‐‑overexpressing  cells[24].  Significantly,  expression  of  the  24  kDa  isoform  
in  cancer  cells  strongly  facilitates  lung  colonization  and  proliferation  in  vivo,  and  
improves  cancer  cell  survival  under  serum  deprivation  in  vitro,  indicating  a  unique  
function  of  nuclear  bFGF  on  cancer  cell  survival  and  metastatic  establishment[25].  
Additionally,  overexpression  of  the  nuclear  isoforms  of  bFGF  correlates  with  a  poor  
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prognosis  in  various  human  cancers[13].  To  date,  neither  expression  nor  function  of  
nuclear  bFGF  in  breast  cancer  has  been  investigated.                
1.4 DNA repair and DNA-dependent protein kinase (DNA-PK)  
Repair  of  DNA  double  strand  breaks  (DSB)  is  critical  for  cell  survival,  especially  
for  cancer  cells  under  the  pressure  of  radiation  and  DNA-­‐‑damaging  chemotherapy.  
Mammalian  cells  have  two  major  pathways  for  DSB  repair:  homologous  recombination  
(HR)  and  non-­‐‑homologous  end  joining  (NHEJ).  HR  is  dependent  on  the  presence  of  a  
sister  chromatid  and  therefore  is  only  available  in  the  late  S  and  G2  phases.  In  contrast,  
NHEJ,  which  occurs  through  out  the  cell  cycle,  joins  the  broken  ends  without  the  need  of  
template,  and  is  the  predominant  pathway  for  DSB  repair[26,  27].    
The  key  component  of  NHEJ  is  DNA-­‐‑dependent  protein  kinase  (DNA-­‐‑PK).  It  
contains  the  Ku70/80  heterodimer  and  the  460  kDa  catalytic  subunit  (DNA-­‐‑PKCS).  After  
DNA  damage,  Ku70/80  binds  to  the  broken  ends,  recruits  DNA-­‐‑PKCS,  and  stimulates  its  
kinase  activity.  Autophosphorylation  at  threonine  2609  and  serine  2056  sites  on  DNA-­‐‑
PKCS  is  required  for  successful  DSB  repair.  Therefore,  DNA-­‐‑PK  activity  is  critical  to  
confer  radioresistance  and  chemoresistance  in  cancer  cells[27-­‐‑29].  Interestingly,  
overexpression  of  nuclear  bFGF  in  HeLa  cells  upregulates  the  expression  of  DNA-­‐‑PKCS  
and  confers  protection  from  ionizing  radiation[30].  Significantly,  BRCA1,  a  tumor  
suppressor  gene  often  dysregulated  in  TN  breast  cancer,  repairs  DNA  double  strand  
breaks  mainly  through  the  HR  pathway[31,  32].  Due  to  frequent  BRCA1  mutation,  TN  
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breast  cancer  cells  should  have  impaired  DNA  repair  ability  and  therefore  are  
vulnerable  to  DNA-­‐‑damaging  chemotherapy[2].  However,  it  is  reasonable  to  postulate  
that  cells  with  high  DNA-­‐‑PKCS  expression  may  overcome  the  shortage  of  BRCA1  and  
thus  become  chemoresistant.    
1.5 Epithelial-mesenchymal transition (EMT)  
The  epithelial-­‐‑mesenchymal  transition  (EMT)  was  first  characterized  as  a  critical  
step  during  early  embryogenesis[33].  Epithelial  cells  are  closely  connected  to  each  other  
and  basement  membrane  through  tight  junctions,  gap  junctions,  desmosomes,  and  
hemi-­‐‑desmosomes.  However,  mesenchymal  cells  are  loosely  connected  to  each  other  
and  have  increased  migratory  capability  and  invasiveness.  The  process  of  EMT  is  
associated  with  downregulation  of  epithelial  cell  markers,  such  as  E-­‐‑cadherin  and  
cytokeratin,  and  upregulation  of  mesenchymal  cell  markers,  including  N-­‐‑cadherin,  
vimentin,  and  fibronectin.  This  process  is  regulated  by  EMT-­‐‑inducing  transcriptional  
factors  (EMT-­‐‑TFs),  namely  Snail,  ZEB1,  and  Twist[34].  EMT  is  closely  related  to  cancer  
metastasis.  In  cancers  arising  from  epithelial  tissues,  primary  tumor  cells  undergo  EMT  
that  empower  them  to  invade  into  surrounding  stroma  tissue  and  intravasate  to  enter  
the  blood  circulation.  These  transformed  mesenchymal-­‐‑like  tumor  cells  extravasate  from  
blood  vessels  and  seed  in  distal  organs  to  form  metastatic  dissemination.  These  
disseminated  tumor  cells  may  maintain  dormancy  for  a  period  time  until  they  
repopulate  to  establish  recurrent  tumors[35]. 
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1.6 Research objectives 
The  overall  goal  of  this  study  is  to  understand  the  mechanisms  underlying  TN  
breast  cancer  dormancy/recurrence.  We  developed  an  in  vitro  model  of  tumor  
recurrence.  Short-­‐‑term  chemotherapy  treatment  of  TN  breast  cancer  cells  enriched  for  
dormant,  chemotherapy-­‐‑resistant  tumor  cells.  Upon  removing  chemotherapy,  these  
dormant  tumor  cells  resumed  growth,  resembling  tumor  recurrence.  Based  on  the  
published  importance  of  bFGF  family  in  therapy  resistance,  we  performed  quantitative  
RT-­‐‑PCR  on  chemo-­‐‑enriched  dormant  cells  and  found  upregulated  bFGF  transcription.  
We  were  surprised  to  see  that  nuclear  but  not  cytosolic  bFGF  was  upregulated  in  
dormant  tumor  cells.  Based  on  these  initial  findings,  we  sought  to  test  the  hypothesis  
that  nuclear  bFGF  signaling  drives  TN  breast  cancer  recurrence.  
To  establish  an  in  vitro  model  for  TN  breast  cancer  dormancy/recurrence,  we  will:  
1)  investigate  the  ability  of  different  chemotherapy  classes  (anthracyclines,  taxanes)  to  
enrich  for  a  dormant  TN  tumor  cell  sub-­‐‑population;  and  2)  determine  whether  these  
dormant  cells  establish  recurrent  colony  formation  upon  chemotherapy  removal.    
To  characterize  the  importance  of  bFGF  signaling  for  TN  breast  cancer  
dormancy/recurrence,  we  will:  1)  measure  nuclear  bFGF  expression  in  chemotherapy-­‐‑
enriched  dormant  and  recurrent  TN  tumor  cells;  2)  determine  the  function  of  bFGF  in  
TN  tumor  dormancy/recurrence  through  knockdown  and  add  back  studies;  and  3)  
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examine  whether  bFGF  expression  in  tumor  samples  is  associated  with  recurrence  in  TN  
breast  cancer  patients.    
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2. Experimental Procedures 
2.1 Methods for establishment of in vitro model of TN breast 
cancer dormancy/recurrence 
2.1.1 Cell culture 
SUM159  triple-­‐‑negative  breast  cancer  cells  were  obtained  from  the  Duke  Cell  
Culture  facility  and  maintained  in  Ham’s  F-­‐‑12  medium  containing  5%  heat-­‐‑inactivated  
FBS,  5  µμg/ml  insulin,  and  1  µμg/ml  hydrocortisone.  BT549  triple-­‐‑negative  breast  cancer  
cells  were  obtained  from  the  Duke  Cell  Culture  Facility  and  maintained  in  RPMI  1640  
containing  10%  heat-­‐‑inactivated  FBS,  1  µμg/ml  insulin,  10  mM  HEPES,  1  mM  pyruvate,  
and  2.5  g/L  glucose.    
2.1.2 Generation of chemotherapy-enriched dormant tumor cells/ 
“recurrent” colonies 
SUM159  tumor  cells  were  seeded  in  T225  cell  culture  flasks  (2  x  106  cells/flask)  
and,  after  2  d,  treated  with  either  1  µμg/ml  doxorubicin  (Sigma,  St.  Louis,  MO)  or  100  nM  
docetaxel  (Sigma,  St.  Louis,  MO).  Drug  was  removed  after  2  d,  and  cells  were  fed  new  
medium  every  third  day.  The  majority  of  cells  (99.9%)  were  eliminated  by  day  8,  after  
which  only  residual  dormant  cells  (0.1%)  were  observed.  BT549  tumor  cells  were  seeded  
in  T225  cell  culture  flasks  (3  x  106  cells/flask)  and,  after  2  d,  treated  with  0.5  µμg/ml  
doxorubicin.  Drug  was  removed  after  2  d,  and  cells  were  fed  new  medium  every  third  
day.  The  majority  of  cells  (99.9%)  were  eliminated  by  day  8,  after  which  only  residual  
dormant  cells  (0.1%)  were  observed.  SUM159  and  BT549  dormant  cells  were  harvested  
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on  day  7  or  8  with  trypsin-­‐‑EDTA,  and  re-­‐‑plated  in  6-­‐‑well  plates.  Medium  was  changed  
every  3-­‐‑4  d.  Recurrent  colonies  were  stained  with  crystal  violet  and  colonies  containing  >  
50  cells  were  counted.    
2.1.3 Time course- Cell death following acute chemotherapy 
treatment 
SUM159  were  incubated  with  doxorubicin  (100  ng/ml)  for  2  d,  after  which  
chemotherapy  was  removed,  and  new  medium  was  added.  Photographs  were  taken  
using  an  Olympus  inverted  microscope  with  a  Canon  EOS  Rebel  T4I.  Final  
magnifications  were  40X  and  100X.  Viable  cell  number  was  determined  at  6  h,  d1,  d2,  d3,  
and  d7  using  trypan  blue  exclusion.    
2.1.4 Time course- Regrowth of chemo-residual tumor cells 
Six  days  after  chemotherapy  removal,  SUM159  cells  were  harvested  with  trypsin,  
and  replated  in  96  well  plates  (1000  cells/well).  Tumor  cell  proliferation  was  assessed  on  
a  daily  basis  by  measuring  [3H]-­‐‑thymidine  uptake.    
2.1.5 Western blots 
Cells  were  harvested  using  trypsin-­‐‑EDTA,  washed  with  PBS,  incubated  in  RIPA  
buffer  on  ice  for  20  min,  and  then  subjected  to  high  speed  centrifugation  to  obtain  total  
cellular  protein  in  the  soluble  fraction.  For  nuclear  protein  extraction,  harvested  cells  
were  incubated  in  cytosolic  lysis  buffer  [(10  mM  HEPES  (pH  7.4),  10  mM  KCl,  1.5  mM  
MgCl2,  0.5%  NP40,  and  proteinase  inhibitors)]  on  ice  for  20  min  and  centrifuged.  
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Supernatants  were  collected  as  cytosolic  protein  lysates.  The  residual  pellets  were  
washed  with  cytosolic  lysis  buffer,  and  then  incubated  in  nuclear  lysis  buffer  [50  mM  
TRIS  (pH  7.5),  1%  SDS,  and  proteinase  inhibitors]  plus  Benzonase  (Sigma,  St.  Louis,  MO)  
on  ice  for  20  min.  The  supernatants  after  centrifugation  were  collected  as  nuclear  protein  
extracts.  Protein  concentrations  were  determined  by  BCA  assay.  Equivalent  amounts  of  
protein  were  subjected  to  SDS-­‐‑polyacrylamide  gel  electrophoresis  (PAGE)  and  
immunoblotted  with  the  following  primary  antibodies,  followed  by  the  appropriate  
species  IRDye-­‐‑conjugated  secondary  antibody  (Life  Technologies,  Carlsbad,  CA):  p21  
(Cell  Signaling,  Beverly,  MA),  Actin  (Sigma,  St.  Louis,  MO),  GAPDH  (GenScript,  
Piscataway,  NJ).  Proteins  were  detected  using  an  Odyssey  infrared  imaging  system  (LI-­‐‑
COR,  Lincoln,  NE).  
2.1.6 Thymidine uptake assay 
Thymidine  Uptake:  Cells  were  plated  in  96-­‐‑well  plates  (3  x  103  cells/well).    After  4  
h,  cells  were  incubated  with  0.5  µμCi/well  [3H]-­‐‑Thymidine  (Perkin  Elmer,  Waltham,  MA)  
for  16  h  before  harvesting  onto  glass-­‐‑fiber  filters.    [3H]-­‐‑Thymidine  incorporation  was  
measured  as  counts  per  minute  (CPM)  using  a  Tri-­‐‑Carb  2100TR  time-­‐‑resolved  liquid  
scintillation  counter  (Perkin  Elmer,  Waltham,  MA).  
2.1.7 Alamar blue cell viability assay 
Cells  were  plated  in  96-­‐‑well  black,  clear  bottom  plates  (2  x  103  cells/well)  in  100  µμl  
complete  medium.    After  4  h,  10  µμl/well  Alamar  Blue  (Life  Technologies,  Carlsbad,  CA)  
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reagent  was  added.  After  2  h,  fluorescence  was  measured  using  a  Cytation3  plate  reader  
(BioTek,  Winooski,  VT)    
2.1.8 PKH26 labeling study 
SUM159  cells  were  labeled  using  the  PKH26  Red  Fluorescent  Cell  Linker  Kit  
(Sigma,  St.  Louis,  MO)  according  to  the  manufacturer’s  instructions.    The  labeled  
SUM159  cells  were  treated  with  doxorubicin  (1  µμg/ml)  to  generate  chemotherapy  
enriched  dormant  cells,  as  described  above.  Labeled  cells  were  detected  using  the  Guava  
EasyCyte  Plus  flow  cytometer  (Millipore,  Billerica,  MA).  
2.2 Methods for mechanistic studies of TN breast cancer 
dormancy/recurrence 
2.2.1 Cell culture 
SUM159  triple-­‐‑negative  breast  cancer  cells  were  obtained  from  the  Duke  Cell  
Culture  facility  and  maintained  in  Ham’s  F-­‐‑12  medium  containing  5%  heat-­‐‑inactivated  
FBS,  5  µμg/ml  insulin,  and  1  µμg/ml  hydrocortisone.  BT549  triple-­‐‑negative  breast  cancer  
cells  were  obtained  from  the  Duke  Cell  Culture  Facility  and  maintained  in  RPMI  1640  
containing  10%  heat-­‐‑inactivated  FBS,  1  µμg/ml  insulin,  10  mM  HEPES,  1  mM  pyruvate,  
and  2.5  g/L  glucose.    
2.2.2 Generation of chemotherapy-enriched dormant tumor cells/ 
“recurrent” colonies 
SUM159  tumor  cells  were  seeded  in  T225  cell  culture  flasks  (2  x  106  cells/flask)  
and,  after  2  d,  treated  with  either  1  µμg/ml  doxorubicin  (Sigma,  St.  Louis,  MO)  or  100  nM  
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docetaxel  (Sigma,  St.  Louis,  MO).  Drug  was  removed  after  2  d,  and  cells  were  fed  new  
medium  every  third  day.  The  majority  of  cells  (99.9%)  were  eliminated  by  day  8,  after  
which  only  residual  dormant  cells  (0.1%)  were  observed.  BT549  tumor  cells  were  seeded  
in  T225  cell  culture  flasks  (3  x  106  cells/flask)  and,  after  2  d,  treated  with  0.5  µμg/ml  
doxorubicin.  Drug  was  removed  after  2  d,  and  cells  were  fed  new  medium  every  third  
day.  The  majority  of  cells  (99.9%)  were  eliminated  by  day  8,  after  which  only  residual  
dormant  cells  (0.1%)  were  observed.  SUM159  and  BT549  dormant  cells  were  harvested  
on  day  7  or  8  with  trypsin-­‐‑EDTA,  and  re-­‐‑plated  in  6-­‐‑well  plates.  Medium  was  changed  
every  3-­‐‑4  d.  Recurrent  colonies  were  stained  with  crystal  violet  and  colonies  containing  >  
50  cells  were  counted.    
2.2.3 Western blots 
Cells  were  harvested  using  trypsin-­‐‑EDTA,  washed  with  PBS,  incubated  in  RIPA  
buffer  on  ice  for  20  min,  and  then  subjected  to  high  speed  centrifugation  to  obtain  total  
cellular  protein  in  the  soluble  fraction.  For  nuclear  protein  extraction,  harvested  cells  
were  incubated  in  cytosolic  lysis  buffer  [10  mM  HEPES  (pH  7.4),  10  mM  KCl,  1.5  mM  
MgCl2,  0.5%  NP40,  and  proteinase  inhibitors]  on  ice  for  20  min  and  centrifuged.  
Supernatants  were  collected  as  cytosolic  protein  lysates.  The  residual  pellets  were  
washed  with  cytosolic  lysis  buffer,  and  then  incubated  in  nuclear  lysis  buffer  [50  mM  
TRIS  (pH  7.5),  1%  SDS,  and  proteinase  inhibitors]  plus  Benzonase  (Sigma,  St.  Louis,  MO)  
on  ice  for  20  min.  The  supernatants  after  centrifugation  were  collected  as  nuclear  protein  
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extracts.  Protein  concentrations  were  determined  by  BCA  assay.  Equivalent  amounts  of  
protein  were  subjected  to  SDS-­‐‑polyacrylamide  gel  electrophoresis  (PAGE)  and  
immunoblotted  with  the  following  primary  antibodies,  followed  by  the  appropriate  
species  IRDye-­‐‑conjugated  secondary  antibody  (Life  Technologies,  Carlsbad,  CA):  bFGF  
(BD  Biosciences,  Franklin  Lakes,  NJ),  Lamin-­‐‑A  (Sigma,  St.  Louis,  MO),  DNA-­‐‑PKCS  (Cell  
Signaling,  Beverly,  MA),  phospho-­‐‑Ser  2056-­‐‑DNA-­‐‑PKCS  (Cell  Signaling,  Beverly,  MA)  
GAPDH  (GenScript,  Piscataway,  NJ).  Proteins  were  detected  using  an  Odyssey  infrared  
imaging  system  (LI-­‐‑COR,  Lincoln,  NE).  
2.2.4 Immunofluorescence 
Cells  were  grown  on  glass  coverslips,  washed  with  Hanks'ʹ  balanced  salt  solution  
(HBSS),  and  fixed  for  30  min  at  room  temperature  in  1%  fresh  formaldehyde  in  PBS.  
After  washing  for  5  min  in  PBS,  the  coverslips  were  incubated  in  5%  bovine  serum  
albumin  (BSA)  in  PBS  for  90  min  at  room  temperature.  Excess  BSA  was  drained  from  the  
coverslips,  and  cells  were  incubated  with  the  primary  bFGF  antibody  (BD  Biosciences,  
Franklin  Lakes,  NJ)  in  PBS  containing  0.5%  BSA  for  overnight  at  4  °C.  The  cells  were  
then  rinsed  three  times  in  PBS  containing  0.1%  Tween  and  incubated  with  secondary  
antibody  (1:400  dilution  of  an  Alexa  Fluor  568-­‐‑conjugated  donkey  anti-­‐‑mouse  IgG)  for  
90  min  at  4  °C  in  the  dark.  The  cells  were  washed  three  times  with  PBS,  incubated  with  a  
1:1000  dilution  of  Hoechst  (Life  Technologies,  Carlsbad,  CA)  for  10  min  at  room  
temperature  in  the  dark,  and  washed  three  times  with  PBS.  The  coverslips  were  dried  
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for  2  h  at  room  temperature,  mounted,  and  cured  overnight  at  4  °C.  Pictures  were  taken  
using  a  fluorescence  microscope  and  analyzed  by  Gen5  image  analysis  software  (BioTek,  
Winooski,  VT).    
2.2.5 Thymidine uptake assay 
Cells  were  plated  in  96-­‐‑well  plates  (3  x  103  cells/well).    After  4  h,  cells  were  
incubated  with  0.5  µμCi/well  [3H]-­‐‑Thymidine  (Perkin  Elmer,  Waltham,  MA)  for  16  h  
before  harvesting  onto  glass-­‐‑fiber  filters.    [3H]-­‐‑Thymidine  incorporation  was  measured  
as  counts  per  minute  (CPM)  using  a  Tri-­‐‑Carb  2100TR  time-­‐‑resolved  liquid  scintillation  
counter  (Perkin  Elmer,  Waltham,  MA).  
2.2.6 Alamar blue cell viability assay 
Cells  were  plated  in  96-­‐‑well  black,  clear  bottom  plates  (2  x  103  cells/well)  in  100  µμl  
complete  medium.    After  4  h,  10  µμl/well  Alamar  Blue  (Life  Technologies,  Carlsbad,  CA)  
reagent  was  added.  After  2  h,  fluorescence  was  measured  using  a  Cytation3  plate  reader  
(BioTek,  Winooski,  VT)    
2.2.7 shRNA and add back transfections 
Cells  were  grown  to  50%  confluence  in  a  10  cm  dish.    The  transfection  mixtures  
contained:  1)  2  µμg  bFGF  or  control  shRNA  plasmid  (Sigma,  St.  Louis,  MO)  with  250  ul  
Optimem  (Life  Technologies,  Carlsbad,  CA)  and  2)  3.8  µμl  of  Lipofectamine  2000  (Life  
Technologies,  Carlsbad,  CA)  with  250ul  Optimem.    These  mixtures  were  incubated  
separately  at  room  temperature  for  5  min,  combined,  and  incubated  for  30  min  at  room  
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temperature.    Cells  were  washed  2X  with  HBSS  (Life  Technologies,  Carlsbad,  CA).    
Optimem  (5.5  ml)  was  then  added  to  the  RNA/Lipofectamine  mixture,  and  this  mix  was  
added  to  the  cells,  which  were  incubated  overnight  at  37˚C.    This  medium  was  removed  
the  next  day  and  replaced  with  medium  containing  puromycin  (5  µμg/mL,  SUM159;  2  
µμg/mL,  BT549).  Cells  were  expanded  in  puromycin  and  tested  for  bFGF  knockdown  by  
western  blotting.  For  bFGF  add  backs,  plasmids(19)  expressing  18  kDa  rat  bFGF,  23  kDa  
rat  bFGF,  or  an  empty  control  were  transfected  into  SUM159  or  BT549  cells  stably  
expressing  a  bFGF  shRNA  .  The  transfection  protocol  was  performed  as  above,  except  
that  the  cells  were  selected  in  puromycin  (as  above)  and  G418  (Life  Technologies,  
Carlsbad,  CA)  at  400  µμg/ml.  Expression  of  addback  contructs  was  assessed  by  western  
blotting  extracts  with  bFGF  antibody.  
2.2.8 Single cell gel electrophoresis assay (Comet assay) 
Cells  were  challenged  with  doxorubicin  (SUM159:  1  µμg/ml,  3h;  BT549:  0.5  µμg/ml,  
4h).  Fresh  medium  was  added  after  chemotherapy  removal.  Cells  were  harvested  at  
sequential  time  points  after  chemotherapy,  mixed  with  low-­‐‑melting-­‐‑point  agarose,  and  
spread  on  CometSlides  using  a  Trevigen  CometAssay®  Kit  (Gaithersburg,  MD).  After  
incubation  with  lysis  solution  and  neutral  solution,  slides  were  subjected  to  
electrophoresis  at  19  V  for  50  min  under  neutral  conditions.  Slides  were  incubated  with  
DNA  precipitation  solution  (1  M  NH4AC,  95%  EtOH)  for  30  min,  followed  by  70%  
ethanol  for  30  min.  Slides  were  then  stained  with  a  1:500  dilution  of  Hoechst  (Life  
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Technologies,  Carlsbad,  CA)  for  15  min  and  washed  with  PBS.  Samples  were  examined  
using  a  fluorescence  microscope,  and  the  presence  of  comet  tails  was  quantified  using  
Gen5  image  analysis  software  (BioTek,  Winooski,  VT).  For  each  time  point,  cells  from  
three  fields  were  analyzed.  Each  field  contained  at  least  50  cells.      
2.2.9 Real-time quantitative RT-PCR 
Total  RNA  from  SUM159  cells  was  extracted  using  PrepEase®  RNA  Spin  Kit  
(USB,  Cleveland,  OH)  and  treated  with  RNase-­‐‑free  DNase  to  remove  residual  genomic  
DNA.  Single-­‐‑stranded  cDNAs  were  synthesized  Use  the  iScript  cDNA  synthesis  kit  from  
Bio-­‐‑Rad  (Hercules,  CA).  Human  FGF2  and  human  DNA-­‐‑PKcs  primers  were  purchased  
from  realtimeprimers.com  (Elkins  Park,  PA).  Real-­‐‑time  PCR  on  the  Mx3005P®  QPCR  
System  (Stratagene,  La  Jolla,  CA)  was  performed  in  the  presence  of  12.5  µμl  VeriQuest™  
Fast  SYBR  Green  qPCR  Master  mix(2x)  (USB,  Cleveland,  OH),  2  µμl  cDNA,  and  H2O  
added  to  a  final  volume  of  25µμl.  The  mixtures  were  denatured  for  5  min  at  95°C,  
followed  by  40  cycles  of  3  s  at  95°C,  and  30  s  at  an  annealing  temperature  at  60°C.  PCR  
products  were  monitored  in  real  time  by  measuring  the  increase  in  fluorescence  caused  
by  the  binding  of  SYBR  Green  I  Dye.  Significance  was  analyzed  using  the  software  
package  MxPro™  QPCR  Software  (Stratagene,  La  Jolla,  CA).    
2.2.10 Selective DNA-PK inhibitor (NU7441) studies 
Cells  were  seeded  in  T225  cell  culture  flasks  (2  x  106  cells/flask)  and,  after  2  d,  
treated  with  1  µμg/ml  doxorubicin  (Sigma,  St.  Louis,  MO)  plus  DMSO  or  NU7441  (1  µμM  
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or  5  µμM,  R&D  Systems,  Minneapolis,  MN).  Drug  was  removed  after  2  d,  and  cells  were  
fed  with  new  medium  every  third  day.  Dormant  cells  were  harvested  on  day  7  with  
trypsin-­‐‑EDTA,  and  re-­‐‑plated  in  6-­‐‑well  plates.  Medium  was  changed  every  3-­‐‑4  d.  
Recurrent  colonies  were  stained  with  crystal  violet  and  colonies  containing  >  50  cells  
were  counted.    
2.2.11 Microarray data analysis 
The  normalized  expression  values  for  bFGF  from  a  breast  cancer  gene  profile  
study[36]  were  obtained  from  the  Oncomine  cancer  gene  expression  database.  The  
subset  data  of  triple-­‐‑negative  breast  cancer  was  pulled.  The  five  year  tumor  recurrence  
status  of  patients  was  compared  to  bFGF  expression  from  pre-­‐‑treatment  biopsy  samples.  
Results  were  presented  using  the  Box-­‐‑Whistler  plot  and  p  values  were  calculated  by  the  
Mann-­‐‑Whitney  U  test.  
2.3 Methods for characterization of recurrent TN breast cancer 
cells 
2.3.1 Cell culture 
SUM159  triple-­‐‑negative  breast  cancer  cells  were  obtained  from  the  Duke  Cell  
Culture  facility  and  maintained  in  Ham’s  F-­‐‑12  medium  containing  5%  heat-­‐‑inactivated  
FBS,  5  µμg/ml  insulin,  and  1  µμg/ml  hydrocortisone.    
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2.3.2 Generation of chemotherapy-enriched dormant tumor cells/ 
“recurrent” colonies 
SUM159  tumor  cells  were  seeded  in  T225  cell  culture  flasks  (2  x  106  cells/flask)  
and,  after  2  d,  treated  with  either  1  µμg/ml  doxorubicin  (Sigma,  St.  Louis,  MO)  or  100  nM  
docetaxel  (Sigma,  St.  Louis,  MO).  Drug  was  removed  after  2  d,  and  cells  were  fed  new  
medium  every  third  day.  The  majority  of  cells  (99.9%)  were  eliminated  by  day  8,  after  
which  only  residual  dormant  cells  (0.1%)  were  observed.  SUM159  dormant  cells  were  
harvested  on  day  7  or  8  with  trypsin-­‐‑EDTA,  and  re-­‐‑plated  in  6-­‐‑well  plates.  Medium  was  
changed  every  3-­‐‑4  d.  Recurrent  colonies  were  stained  with  crystal  violet  and  colonies  
containing  >  50  cells  were  counted.    
2.3.3 Western blots 
Cells  were  harvested  using  trypsin-­‐‑EDTA,  washed  with  PBS,  incubated  in  RIPA  
buffer  on  ice  for  20  min,  and  then  subjected  to  high  speed  centrifugation  to  obtain  total  
cellular  protein  in  the  soluble  fraction.  For  nuclear  protein  extraction,  harvested  cells  
were  incubated  in  cytosolic  lysis  buffer  [10  mM  HEPES  (pH  7.4),  10  mM  KCl,  1.5  mM  
MgCl2,  0.5%  NP40,  and  proteinase  inhibitors]  on  ice  for  20  min  and  centrifuged.  
Supernatants  were  collected  as  cytosolic  protein  lysates.  The  residual  pellets  were  
washed  with  cytosolic  lysis  buffer,  and  then  incubated  in  nuclear  lysis  buffer  [50  mM  
TRIS  (pH  7.5),  1%  SDS,  and  proteinase  inhibitors]  plus  Benzonase  (Sigma,  St.  Louis,  MO)  
on  ice  for  20  min.  The  supernatants  after  centrifugation  were  collected  as  nuclear  protein  
extracts.  Protein  concentrations  were  determined  by  BCA  assay.  Equivalent  amounts  of  
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protein  were  subjected  to  SDS-­‐‑polyacrylamide  gel  electrophoresis  (PAGE)  and  
immunoblotted  with  the  following  primary  antibodies,  followed  by  the  appropriate  
species  IRDye-­‐‑conjugated  secondary  antibody  (Life  Technologies,  Carlsbad,  CA):  N-­‐‑
cadherin  (Thermo  Fisher,  Waltham,  MA),  Pan-­‐‑cytokeratin  (Cell  Signaling,  Beverly,  MA),  
MMP-­‐‑2  (Millipore,  Billerica,  MA),  c-­‐‑Jun  (Cell  Signaling,  Beverly,  MA),  phospho-­‐‑Ser  63-­‐‑c-­‐‑
Jun  (Cell  Signaling,  Beverly,  MA),  bFGF  (BD  Biosciences,  Franklin  Lakes,  NJ),  Lamin-­‐‑A  
(Sigma,  St.  Louis,  MO),  DNA-­‐‑PKCS  (Cell  Signaling,  Beverly,  MA),  phospho-­‐‑Ser  2056-­‐‑
DNA-­‐‑PKCS  (Cell  Signaling,  Beverly,  MA),  Histone  H2A.X  (Cell  Signaling,  Beverly,  MA),  
GAPDH  (GenScript,  Piscataway,  NJ).  Proteins  were  detected  using  an  Odyssey  infrared  
imaging  system  (LI-­‐‑COR,  Lincoln,  NE).  
2.3.4 Thymidine uptake assay 
Cells  were  plated  in  96-­‐‑well  plates  (2  x  103  cells/well).    After  overnight  
incubation,  cells  were  treated  with  doxorubicin  (Sigma,  St.  Louis,  MO)  at  different  
concentrations  (0-­‐‑100  ng/ml)  or  docetaxel  (Sigma,  St.  Louis,  MO)  at  different  
concentrations  (0-­‐‑10  nM)  for  48  h.  Cells  were  incubated  with  0.5  µμCi/well  [3H]-­‐‑
Thymidine  (Perkin  Elmer,  Waltham,  MA)  for  16  h  before  harvesting  onto  glass-­‐‑fiber  
filters.    [3H]-­‐‑Thymidine  incorporation  was  measured  as  counts  per  minute  (CPM)  using  
a  Tri-­‐‑Carb  2100TR  time-­‐‑resolved  liquid  scintillation  counter  (Perkin  Elmer,  Waltham,  
MA).  
    23  
2.3.5 Wound-healing migration assay 
Tumor  cells  from  recurrent  colonies,  as  well  as  parental  tumor  cells,  were  plated  
on  a  24-­‐‑well  plate  and  grew  to  reach  confluence.  Cells  in  the  middle  of  each  well  were  
mechanically  scratched  using  a  20  µμl  pipette  tip.  Cell  debris  were  removed  by  PBS  wash.  
Fresh  medium  was  added.  Images  were  taken  on  0  h  and  8  h  using  an  Olympus  inverted  
microscope  with  a  Canon  EOS  Rebel  T4I.  At  least  three  random  locations  were  examined  
and  representative  pictures  were  shown.    
2.3.6 Transwell invasion assay 
Tumor  cells  from  recurrent  colonies,  as  well  as  parental  tumor  cells,  were  serum-­‐‑
starved  for  24  h.  Equal  amounts  of  cells  were  added  to  the  upper  chambers  of  a  matrigel-­‐‑
coated  plate  (Corning,  Tewksbury,  MA).  Completed  medium  was  added  to  the  bottom  
chambers.  After  12  h,  cells  that  migrated  into  the  bottom  chambers  were  fixed  and  
stained  with  crystal  violet.  The  number  of  migrated  cells  was  counted  from  three  fields  
using  an  Olympus  inverted  microscope  with  a  Canon  EOS  Rebel  T4I.
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3. Development of an in vitro Model of TN Breast Cancer 
Dormancy/Recurrence 
3.1 Introduction 
Despite  the  apparent  efficacy  of  chemotherapy  in  “shrinking”  primary  tumors,  
chemotherapy-­‐‑resistant  tumor  cells  are  thought  to  contribute  to  future  tumor  recurrence,  
the  leading  cause  of  patient  mortality.  The  identification  of  proteins  that  confer  
chemotherapy  resistance  has  historically  relied  on  studies  of  signaling  pathways  
supported  by  tumor  cells  subjected  to  long-­‐‑term  drug  selection.  These  long-­‐‑term  
selection  models  select  for  mutations/epigenetic  modifications  that  result  in  acquired  
expression/activity  of  proteins  involved  in  therapy  resistance.    
Other  models  propose  that  tumors  are  heterogeneous,  consisting  of  therapy-­‐‑
sensitive  and  therapy-­‐‑resistant  tumor  cell  subpopulations.  According  to  these  models,  
following  chemotherapy  treatment,  chemo-­‐‑resistant  tumor  cells  exist  in  a  dormant  
(sleeping)  state  for  many  years  before  resuming  growth,  resulting  in  tumor  recurrence.  
Methods  are  needed  to  enrich  for  dormant  tumor  cells,  allowing  for  studies  of  their  
unique  signaling  properties.    Such  studies  will  be  critical  to  defining  logical  therapeutic  
targets  for  preventing  tumor  recurrence.    
Using  short  term  chemotherapy  treatment  to  enrich  for  drug-­‐‑resistant  tumor  
cells,  we  have  developed  an  in  vitro  model  of  tumor  recurrence.  In  this  model,  short-­‐‑
term  exposure  of  TN  breast  tumor  cells  to  clinical-­‐‑relevant  chemotherapy  classes/doses  
enriches  for  a  population  of  slow-­‐‑cycling  (dormant)  tumor  cells.  Chemotherapy-­‐‑
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enriched  dormant  tumor  cells  resume  proliferation  after  chemotherapy  withdrawal,  
forming  colonies  resembling  a  tumor  recurrence.  Contrasting  with  evolution  models  of  
therapy  resistance,  the  existence  of  drug-­‐‑resistant  tumor  cell  subpopulations  in  the  
original  tumor  suggests  that  we  can  effectively  eliminate  tumor  recurrence  by  
implementing  combination  therapies  (chemotherapy  targeting  proliferative  cells  +  
therapy  targeting  drug-­‐‑resistant  dormant  cells).    
3.2 Results 
3.2.1 Generation of dormant tumor cells and “recurrent” colonies by 
doxorubicin 
Several  studies  indicate  that  drug-­‐‑resistant,  slow-­‐‑cycling  tumor  cells  are  
represented  at  low  frequency  in  human  tumors,  and  are  therapy  resistant  [37,  38].  The  
contribution  of  these  cells  to  tumor  recurrence  following  chemotherapy  treatment  is  not  
known.  We  investigated  the  hypothesis  that  short-­‐‑term  exposure  of  tumor  cells  to  
chemotherapy  enriches  for  a  slow-­‐‑cycling,  chemo-­‐‑resistant  tumor  cell  sub-­‐‑population  
that  can,  over  time,  resume  growth,  thus  resembling  tumor  recurrence.  To  test  this  
hypothesis,  we  exposed  human  TN  breast  cancer  cells  to  acute  chemotherapy  treatment.  
SUM159  and  BT549  TN  breast  tumor  cells  were  exposed  to  doxorubicin  at  clinical-­‐‑
relevant  concentration  (1  µμg/ml  and  0.5  µμg/ml,  respectively)[39].  Doxorubicin  was  
removed  on  d2,  and  fresh  culture  medium  was  added.  After  7  or  8  days  (SUM159),  the  
majority  of  tumor  cells  were  dead.  However,  we  noted  that  a  small  number  of  residual  
tumor  cells  remained.  These  residual  tumor  cells  appeared  to  be  non-­‐‑proliferative,  as  
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indicated  by  the  fact  that  their  numbers  did  not  increase  for  several  days  (data  not  
shown).  Approximately  12  d  after  chemotherapy  removal,  these  residual  tumor  cells  
resumed  proliferation  and  eventually  formed  colonies,  resembling  a  tumor  recurrence  
(Fig.  3).    
  
Figure  3:  Generation  of  dormant  tumor  cells  and  “recurrent”  colonies  by  
doxorubicin[40].  SUM159  and  BT549  TN  breast  tumor  cells  were  treated  with  
doxorubicin  (1  µμg/ml,  0.5  µμg/ml,  respectively)  for  2  d,  after  which  chemotherapy  was  
removed  and  fresh  medium  was  added.  Between  7  and  10  d,  a  small  number  of  dormant  
cells  (0.1%  of  the  original  population)  remained,  and  exhibited  significantly  reduced  
proliferation  compared  to  parental  (untreated)  cells.  Approximately  2  weeks  after  
chemotherapy  withdrawal,  the  dormant  cells  resumed  proliferation  and  established  
“recurrent”  colonies.  Pictures  of  parental  (untreated),  dormant,  and  recurrent  cells  were  
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3.2.2 Generation of dormant tumor cells and “recurrent” colonies by 
docetaxel 
To  determine  whether  chemo-­‐‑resistant  tumor  cell  sub-­‐‑population  can  be  
enriched  by  microtubule-­‐‑modifying  agents,  we  exposed  SUM159  TN  breast  tumor  cells  
to  docetaxel  (100  nM).  Docetaxel  was  removed  on  d2  for  SUM159  cells,  and  fresh  culture  
medium  was  added.  After  8  days,  the  majority  of  tumor  cells  were  dead.  However,  we  
noted  that  a  small  number  of  residual  tumor  cells  remained.  These  residual  tumor  cells  
appeared  to  be  non-­‐‑proliferative,  as  indicated  by  the  fact  that  their  numbers  did  not  
increase  for  several  days  (data  not  shown).  Approximately  10  d  after  chemotherapy  
removal,  these  residual  tumor  cells  resumed  proliferation  and  eventually  formed  
colonies,  resembling  a  tumor  recurrence  (Fig.  4).    
 
  
Figure  4:  Generation  of  dormant  tumor  cells  and  “recurrent”  colonies  by  
docetaxel[41].  SUM159  TN  breast  tumor  cells  were  treated  with  docetaxel  (100  nM)  for  2  
d,  after  which  chemotherapy  was  removed  and  fresh  medium  was  added.  Between  7  
and  10  d,  a  small  number  of  dormant  cells  (0.1%  of  the  original  population)  remained,  
and  exhibited  significantly  reduced  proliferation  compared  to  parental  (untreated)  cells.  











	  	  	  	  Residual tumor cells  
                Day 8 
    28  
Approximately  2  weeks  after  chemotherapy  withdrawal,  the  dormant  cells  resumed  
proliferation  and  established  “recurrent”  colonies.  Pictures  of  parental  (untreated),  
dormant,  and  recurrent  cells  were  taken  on  d  0,  8,  18,  respectively.  Magnification  20X.  
 
3.2.3 Morphology of dormant tumor cells 
Previous  studies  suggest  that  short-­‐‑term  chemotherapy  can  induce  reversible  
cellular  senescence  that  is  associated  with  chemoresistance  in  several  types  of  cancer,  
including  breast  cancer[6,  11,  12].  Correspondingly,  the  chemotherapy-­‐‑enriched  
dormant  cells  in  our  model  also  have  distinctive  morphologic  features-­‐‑-­‐‑flattened  and  
enlarged  cytoplasm  (>5  times  larger  than  untreated  parental  cells),  similar  to  senescent-­‐‑
like  morphology  (Fig.  5).    
  
      
                        
Figure  5:  Morphology  of  dormant  tumor  cells.  A.  Pictures  of  dormant  cells  on  showing  
distinctive  morphologic  features:  enlarged  cytoplasm,  “fried  egg”  appearance,  or  stellar  
protrusions.  Note  the  two  lower  pictures  also  contain  recurrent  cells  that  are  much  
smaller  in  size.  Magnification  100X.  B.  Flow  cytometry  shows  increased  cell  size  (as  
indicated  by  forward  scatter)  in  chemotherapy-­‐‑enriched  dormant  tumor  cells  compared  
to  untreated  parental  cells.    
A B 
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3.2.4 Pre-existence of dormant tumor cells in parental tumor cell lines 
Previous  studies  indicate  that  tumors  are  heterogeneous,  consisting  of  distinct  
tumor  cell  subpopulations[42,  43].  To  determine  if  the  dormant  cells  generated  in  our  
model  after  short-­‐‑term  chemotherapy  exposure  represent  a  subpopulation  of  cells  in  the  
original  tumor  cell  line,  we  performed  a  label  retention  study  using  the  label  retaining  
dye  PKH26.  Unlike  parental  tumor  cells,  which  lose  this  dye  upon  cell  division,  dormant  
tumor  cells  surviving  chemotherapy  treatment  retained  this  dye  (Fig.  6).  This  finding  
indicates  that  dormant  tumor  cells  generated  in  our  chemotherapy  model  are  non-­‐‑




Figure  6:  Dormant  tumor  cells  are  represented  in  parental  tumor  cell  lines  and  
enriched  by  chemotherapy  treatment[41].  SUM159  cells  were  stained  with  the  label-­‐‑
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incubated  for  2  d  with  doxorubicin  (1  µμg/ml;  yellow  line).  The  percentage  of  label-­‐‑
retaining  cells  was  determined  on  d8  after  treatment.  Note  that  at  the  time  of  harvest,  
untreated  cells  (proliferative)  had  lost  the  dye,  whereas  pre-­‐‑existing  dormant  cells  
enriched  by  chemotherapy  had  retained  the  dye.  
  
3.2.5 Dormant tumor cells exhibit reduced proliferation but 
metabolically active state 
In  its  most  simple  form,  tumor  dormancy  has  been  defined  as  a  condition  in  
which  residual  cancer  cells  stop  dividing[44].  It  is  thought  that  these  cells  remain  
dormant  for  a  prolonged  period  before  receiving  signals  (intrinsic  or  extrinsic)  that  cause  
them  to  resume  growth  and  establish  recurrent  tumors.  Fitting  this  definition  of  
dormancy,  both  SUM159  and  BT549  cells  surviving  short  term  chemotherapy  in  our  
model  represented  a  sub-­‐‑population  of  cells  that  did  not  take  up  appreciable  thymidine,  
but  were  metabolically  active,  as  indicated  using  an  alamar  blue  assay  (Fig.  7A  and  B).  
Notably,  chemo-­‐‑residual  BT549  cells  exhibited  increased  alamar  blue  positivity  
compared  to  parental  BT549  cells,  suggesting  that  these  enriched  cells  may  have  
elevated  metabolism.  Chemo-­‐‑residual  tumor  cells  also  expressed  increased  levels  of  p21  
(Fig.  7C),  a  cell  cycle  arrest  protein.  
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Figure  7:  Dormant  tumor  cells  maintain  in  a  non-­‐‑proliferative  but  metabolically  active  
state[40,  41].  A  and  B.  SUM159  (A)  and  BT549  (B)  cells  were  exposed  to  acute  
doxorubicin  treatment  (as  described  in  Fig.  1).  Residual  tumor  cells  surviving  short-­‐‑term  
chemotherapy  treatment  were  harvested  on  d8,  and  seeded  at  2000  cells/well  in  triplicate  
wells  of  a  96  well  plate.  Proliferation  was  determined  by  [3H]-­‐‑thymidine  incorporation  
(+/-­‐‑SD).  Cell  viability  was  assessed  by  alamar  blue  (fluorescence  +/-­‐‑  SD).  n=6,  error  bars  
represent  S.D.,  ***p<0.001,  two-­‐‑tailed  student’s  t-­‐‑test.  C.  Total  cellular  protein  was  
extracted  from  parental  and  dormant  SUM159  cells,  and  equivalent  amounts  were  
immunoblotted  with  p21  antibody,  followed  by  IrDye-­‐‑conjugated  secondary  antibody.  
Protein  loading  was  assessed  using  Actin  antibody.  Similar  results  were  obtained  in  
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3.2.6 Dormant tumor cells resume growth and establish recurrent 
colonies 
We  next  sought  to  determine  the  time  after  chemotherapy  removal  that  dormant  
tumor  cells  resumed  growth  after  chemotherapy  removal.  The  number  of  viable  breast  
tumor  cells  decreased  for  five  days  after  chemotherapy  removal,  as  demonstrated  in  Fig.  
8A  and  B.    However,  residual  tumor  cells  did  not  resume  proliferation  until  
approximately  10  days  after  chemotherapy  removal,  as  assessed  by  [3H]-­‐‑thymidine  
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Figure  8:  Kinetics  of  recurrent  colony  growth[41].  SUM159  tumor  cells  were  incubated  
with  doxorubicin  (2d)  as  indicated  in  Fig.1.  A  and  B.  Kinetics  of  cell  die-­‐‑off  were  
assessed  by  imaging  representative  fields  (A)  as  well  as  by  counting  viable  cells  using  
trypan  blue  (B)  at  the  indicated  times.  C.  Proliferative  status  of  residual  tumor  cells  was  
measured  over  time  by  performing  [3H]-­‐‑thymidine  incorporation  assays  on  cells  
harvested  at  the  indicated  times  (2000  cells/well).  
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3.3 Discussion 
Our  results  demonstrate  that  dormant,  chemo-­‐‑resistant  tumor  cells  can  be  
enriched  from  breast  cancer  cell  lines  by  short-­‐‑term  chemotherapy  treatment.  DNA-­‐‑
damaging  (doxorubicin)  and  microtubule-­‐‑modifying  (docetaxel)  chemotherapies,  
representing  standard  treatment  regimens  for  TN  breast  cancer  patients,  enriched  for  
these  dormant  cells  at  clinically  relevant  doses[45,  46],  indicating  broad  relevance  to  
patient  treatment  (Fig.  1A  and  B).      
Traditional  models  of  tumor  recurrence  focus  on  the  modifications  occurring  in  
tumor  cells  upon  long-­‐‑term  drug  selection.  These  long-­‐‑term  selection  models  select  for  
mutations/epigenetic  modifications  that  result  in  acquired  expression/activity  of  
proteins  involved  in  therapy  resistance[38,  47].  In  contrast,  our  model  enriches  for  the  
“culprit”  dormant  tumor  cells  by  short  term  chemotherapy.    
Our  in  vitro  model  of  tumor  dormancy/recurrence  is  important  because  it  
enriches  for  a  dormant  tumor  cell  population  that  is  normally  under-­‐‑represented  in  the  
parental  tumor  cell  line.  This  model  provides  us  a  platform  to  facilitate  studies  on  
identifying  novel  signaling  pathways  that  drive  tumor  dormancy/recurrence.  These  
studies  have  the  potential  to  identify:  1)  logical  therapeutic  targets  on  chemo-­‐‑resistant,  
dormant  tumor  cell  populations,  and  2)  biomarkers  that  predict  recurrence-­‐‑free  survival.  
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4. bFGF Regulation of TN Breast Cancer Dormancy/ 
Recurrence 
4.1 Introduction 
Although  tumor  recurrence  is  frequently  observed  after  chemotherapy  treatment  
of  aggressive  breast  cancers,  little  is  known  about  the  signaling  pathways  that  contribute  
to  TN  breast  cancer  recurrence.    
The  basic  fibroblast  growth  factor  family  (bFGF;  alternative  name:  FGF-­‐‑2)  
consists  of  both  cytosolic  (secreted)  and  nuclear  isoforms.  Expression  of  these  bFGF  
isoforms  is  regulated  at  the  level  of  translation.  Specifically,  cytosolic  isoforms  (low  
molecular  weight,  18  kDa)  are  regulated  by  CAP-­‐‑dependent  translation,  whereas  
nuclear  isoforms  (high  molecular  weight;  22,  22.5,  and  24  kDa)  are  regulated  by  CAP-­‐‑
independent  translation[48].  These  isoforms  differ  in  molecular  weight  because  they  
utilize  different  translation  initiation  sites.  
Cytosolic  (secreted)  isoforms  of  basic  fibroblast  growth  factor  (bFGF)  have  been  
implicated  in  tumor  resistance  to  anti-­‐‑angiogenic  therapy[18-­‐‑23].  However,  functions  for  
nuclear  bFGF  in  cancer  cells  remain  poorly  understood.  In  over-­‐‑expression  models,  
nuclear  bFGF  has  been  reported  to  regulate  cell  cycle[49-­‐‑51],  cell  survival[25],  
radioresistance[30],  and  tumor  metastasis[25,  52].  Moreover,  nuclear  bFGF  expression  in  
astrocytic  tumors  is  associated  with  a  poor  patient  prognosis[53].  To  date,  nuclear  bFGF  
expression/function  in  breast  cancer  has  not  been  investigated.    
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DNA  repair  pathways  are  frequently  de-­‐‑regulated  in  breast  cancer.  While  BRCA  
proteins  are  responsible  for  homologous  repair,  DNA-­‐‑dependent  protein  kinase  (DNA-­‐‑
PK)  repairs  double-­‐‑stranded  DNA  breaks  by  non-­‐‑homologous  end  joining.  DNA-­‐‑PK  
consists  of  a  catalytic  subunit  (DNA-­‐‑PKcs)  and  a  regulatory  subunit  (Ku70/80  
heterodimer),  which  recruit  DNA-­‐‑PKcs  to  DNA.  The  status  of  the  cell  cycle  determines  
whether  DNA-­‐‑PK  or  BRCA  repairs  DNA,  with  DNA-­‐‑PK  being  responsible  in  growth  
arrested  cells[54].  
Previous  studies  using  bFGF  overexpression  models  suggest  that  nuclear  bFGF  
drives  DNA-­‐‑PKcs  transcription[30],  but  an  ability  of  endogenous  bFGF  to  regulate  
DNA-­‐‑PKcs  expression/DNA  repair  in  tumor  cells  has  not  been  reported.  In  the  current  
work,  we  show  that  chemo-­‐‑residual  dormant  TN  tumor  cells  are  dependent  on  a  nuclear  
bFGF/DNA-­‐‑PKcs  signaling  axis  for  their  survival  and  resumed  proliferation  following  
chemotherapy  treatment.  Our  work  identifies  a  novel  signaling  axis  that  likely  
contributes  to  TN  breast  cancer  recurrence.  
  
4.2 Results 
4.2.1 Chemotherapy-enriched dormant cells have increased bFGF 
mRNA level 
To  determine  whether  bFGF  expression  is  associated  with  tumor  dormancy,  we  
performed  quantitative  RT-­‐‑PCR  analysis  using  RNA  extracted  from  parental  and  
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dormant  SUM159  cells.  Chemotherapy-­‐‑enriched  dormant  cells  exhibited  increased  bFGF  
mRNA  compared  to  parental  tumor  cells  (Fig.  9).  
  
Figure  9:  bFGF  mRNA  level  in  dormant  tumor  cells[40].  Increased  bFGF  mRNA  in  
dormant  SUM159  cells  after  doxorubicin  treatment  as  described  in  Fig.  1A.  Total  RNA  
was  extracted  from  parental  and  dormant  cells.  bFGF  mRNA  was  quantified  by  qRT-­‐‑
PCR,  and  is  shown  as  fold  increase  to  β-­‐‑actin.  Error  bars  represent  S.D.,  n=3,  **p<0.01,  
two-­‐‑tailed  student’s  t-­‐‑test.  
  
4.2.2 Chemotherapy-enriched dormant cells express increased 
nuclear bFGF 
To  elucidate  the  connection  between  different  isoforms  of  bFGF  and  tumor  
dormancy,  we  measured  nuclear  and  cytosolic  bFGF  levels  in  chemotherapy-­‐‑enriched  
dormant  tumor  cells.  Western  blot  results  showed  significantly  increased  levels  of  
nuclear  bFGF  isoforms  (22,  24  kD),  but  not  the  cytosolic  bFGF  isoform  (18  kD),  in  
dormant  cells  compared  to  parental  cells  (Fig.  1D).  This  trend  was  observed  regardless  
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Figure  10:  Dormant  tumor  cells  express  increased  nuclear  bFGF[40].  A.  Increased  
expression  of  nuclear,  but  not  cytosolic,  bFGF  in  dormant  SUM159  cells  after  
doxorubicin  or  docetaxel  treatment  (as  described  in  Fig.  1A).  Nuclear  or  cytosolic  
protein  was  extracted  from  parental  and  dormant  cells.  Equivalent  amounts  were  
immunoblotted  with  bFGF,  Lamin  A,  or  GAPDH  antibody,  followed  by  IrDye-­‐‑
conjugated  secondary  antibodies.  Protein  bands  were  detected  by  infrared  imaging.  B.  
Protein  bands  from  three  independent  trials  (doxorubicin  treatment,  as  described  in  Fig.  
1A)  were  quantified  using  Image  J  software  (NIH),  and  the  relative  ratio  of  nuclear  bFGF  
to  loading  control  is  shown  for  parental  and  dormant  SUM159  cells.  Error  bars  represent  
S.D.,  n=3,  ***p<0.001,  two-­‐‑tailed  student’s  t-­‐‑test.  
  
4.2.3 Immunofluorescence for bFGF in dormant tumor cells 
By  immunofluorescence,  we  confirmed  increased  nuclear  bFGF  in  dormant  
relative  to  parental  TN  tumor  cells  for  both  SUM159  and  BT549  tumor  cells  (Fig.  11)  as  
well  as  for  two  other  TN  breast  tumor  cell  lines  (HS578T  and  MDA-­‐‑MB-­‐‑231,  data  not  
shown).  These  results  suggest  an  association  of  nuclear  bFGF  expression  with  TNBC  
dormancy  following  chemotherapy  treatment.  
  















































Figure  11:  Immunofluorescence  for  bFGF  in  dormant  tumor  cells[40].  SUM159  and  
BT549  cells  were  treated  with  doxorubicin  as  described  in  Fig.  1A.  Parental  and  dormant  
cells  were  fixed  and  stained  with  Hoechst  (blue)  and  bFGF  antibody  (red)  to  
demonstrate  the  increased  nuclear  localization  of  bFGF  in  dormant  TN  breast  tumor  
cells.  Magnification  40X.    
  
                           SUM159                                
     Untreated             Dox-enriched dormant  
                            BT549                                 
     Untreated             Dox-enriched dormant  
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4.2.4 bFGF knockdown in TN breast tumor cells reduces the number 
of chemo-enriched dormant cells 
To  determine  whether  bFGF  is  required  for  TNBC  dormancy  and  recurrence,  we  
knocked  down  bFGF  expression  in  SUM159  and  BT549  cells  by  stable  bFGF  shRNA  
transfection  (Fig.  12A).  Cells  transfected  with  bFGF  or  control  shRNA  were  treated  for  
2d  with  doxorubicin  as  in  Fig.  1A.  The  number  of  dox-­‐‑enriched  dormant  cells  on  day  7  
was  significantly  decreased  in  bFGF  shRNA  transfectants  compared  to  control  shRNA  
transfectants  (Fig.  12B  and  C).  
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Figure  12:  A.  bFGF  knockdown  in  TN  breast  tumor  cells  reduces  the  number  of  
chemo-­‐‑enriched  dormant  cells[40].  A.  SUM159  and  BT549  cells  were  transfected  stably  
with  a  bFGF  shRNA  or  control  shRNA.  The  knockdown  of  nuclear  bFGF  was  confirmed  
by  immunoblotting  equivalent  amounts  of  nuclear  extract  with  bFGF  antibody.  Protein  
loading  was  accessed  using  Lamin  A  antibody.  Protein  bands  were  quantified  using  
Image  J  software  (NIH),  and  the  relative  ratio  of  bFGF  to  loading  control  is  shown  for  
each  lane.  B  and  C.  SUM159  cells  (B)  and  BT549  cells  (C)  transfected  stably  with  a  bFGF  
shRNA  or  control  shRNA  were  treated  with  doxorubicin  as  described  in  Fig.  1A.  Upper  
panel:  Pictures  of  remaining  dormant  cells  were  taken  on  d7.  Magnification  20X.  Lower  
panel:  Numbers  of  chemotherapy-­‐‑enriched  dormant  cells  on  d7  were  determined  by  
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4.2.5 bFGF knockdown in TN breast tumor cells decreases recurrent 
colony formation 
To  further  characterize  whether  bFGF  is  required  for  dormant  tumor  cell  
regrowth  and  recurrent  colony  formation,  we  treated  the  above  mentioned  shRNA-­‐‑
transfected  cells  with  doxorubicin  for  2d  as  in  Fig.  3.  The  numbers  of  recurrent  colonies  
(>50  cells)  were  quantified.  bFGF  shRNA  transfectants  formed  dramatically  fewer  
recurrent  colonies  after  chemotherapy  removal  than  control  shRNA  transfectants  (Fig.  
13).  Collectively,  these  results  indicate  that  bFGF  is  necessary  for  the  survival  of  
dormant  tumor  cells  after  doxorubicin  challenge  and  subsequent  “recurrent”  colony  
formation.  
  
Figure  13:  bFGF  knockdown  in  TN  breast  tumor  cells  decreases  recurrent  colony  
formation[40].  SUM159  cells  (A)  and  BT549  cells  (B)  transfected  stably  with  a  bFGF  
shRNA  or  control  shRNA  were  treated  with  doxorubicin  as  described  in  Fig.  1A.  Upper  
panel:  Recurrent  colonies  (containing  >  50  cells)  were  quantified  on  the  indicated  days.  
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Recurrent  colonies  were  fixed  and  stained  with  crystal  violet  on  d22  (SUM159  cell)  and  
d24  (BT549  cell).  Similar  results  were  obtained  in  at  least  3  independent  trials.  
  
4.2.6 Nuclear bFGF isoform promotes the survival of chemo-residual, 
dormant tumor cells 
The  bFGF  shRNA  used  in  this  study  knocks  down  expression  of  both  nuclear  
and  cytosolic  bFGF  isoforms.  To  determine  which  bFGF  isoform  facilitates  dormant  
tumor  cell  survival  and  “recurrent”  colony  formation  in  our  model,  we  transfected  bFGF  
shRNA-­‐‑expressing  cells  with  a  vector  expressing  18  kDa  rat  bFGF,  23  kDa  rat  bFGF,  or  
an  empty  control  vector  (Fig.  14A).  The  18  kDa  and  23  kDa  rat  bFGF  constructs  exhibit  
97%  and  82%  homology  with  human  18  kDa  and  24  kDa  nuclear  bFGF,  respectively[55].  
The  addback  of  the  23  kDa  rat  nuclear  bFGF,  but  not  the  18  kDa  rat  cytosolic  bFGF,  to  
bFGF  shRNA  transfectants  increased  the  number  of  chemo-­‐‑residual  dormant  tumor  cells  
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Figure  14:  Transfection  of  bFGF  knockdown  cells  with  HMW  (nuclear)  bFGF  vector  
restores  dormant  cell  survival[40].  A.  bFGF  shRNA-­‐‑transfected  SUM159  cells  were  
transfected  with  vectors  expressing  LMW  (cytosolic)  bFGF,  HMW  (nuclear)  bFGF,  or  
pCI  as  a  vector  control.  The  expression  of  addback  constructs  in  stable  transfectants  was  
confirmed  and  compared  to  control  shRNA-­‐‑transfected  cells  by  immunoblotting  
equivalent  amounts  of  nuclear  extract  with  bFGF  antibody.  Protein  loading  was  assessed  
using  Lamin  A  antibody.  B.  SUM159  cells  expressing  control  shRNA,  bFGF  shRNA,  or  
bFGF  shRNA  plus  indicated  addback  constructs  were  treated  with  doxorubicin  as  
described  in  Fig.  1A.  The  number  of  chemotherapy-­‐‑enriched  dormant  cells  was  
determined  on  d7  by  trypan  blue  exclusion.  Error  bars  represent  S.D.,  n=3,  ***p<0.001,  
two-­‐‑tailed  student’s  t-­‐‑test.  
  
4.2.7 Nuclear bFGF isoform promotes recurrent colony formation 
Likewise  addback  of  the  23  kDa  bFGF  isoform  restored  the  ability  of  bFGF  
shRNA  transfectants  to  establish  recurrent  colonies  following  short  term  doxorubicin  
treatment  (Fig.  15).  Collectively,  these  results  demonstrate  that  high  molecular  weight  
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Figure  15:  Transfection  of  bFGF  knockdown  cells  with  HMW  (nuclear)  bFGF  vector  
restores  recurrent  colony  formation[40].  Upper  panel:  Recurrent  SUM159  colonies  
(containing  >  50  cells)  were  quantified  on  the  indicated  days.  Error  bars  represent  S.D.,  
n=3,  ***p<0.001,  two-­‐‑tailed  student’s  t-­‐‑test.  Lower  panel:  Recurrent  colonies  were  fixed  
and  stained  with  crystal  violet  on  d20.  Similar  results  were  obtained  in  at  least  3  
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4.2.8 Chemotherapy-enriched dormant tumor cells exhibit accelerated 
DNA double strand break repair 
Elevated  DNA  repair  activity  is  associated  with  chemoresistance  in  many  
tumors[29,  56-­‐‑58].  To  compare  the  DNA  double  strand  break  (DSB)  repair  capability,  we  
re-­‐‑challenged  the  untreated  parental  cells  and  chemo-­‐‑enriched  dormant  cells  with  
doxorubicin  (DNA  damaging  agent)  for  3  h  and  examined  their  recovery  by  neutral  
comet  assay.  The  percentage  of  cells  with  comet  tails  returned  to  baseline  faster  in  
dormant  cells  than  in  parental  cells.  Similar  results  were  observed  in  both  SUM159  (Fig.  
16A)  and  BT549  (Fig.  16B)  dormancy  models.  This  data  indicates  that  chemotherapy-­‐‑
enriched  dormant  tumor  cells  repaired  DNA  double  strand  breaks  more  quickly  than  
parental  cells.  
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Figure  16:  Dormant  tumor  cells  have  higher  DNA  repair  capability[40].  A.  Left  panel:  
SUM159  dormant  cells  and  parental  (untreated)  cells  were  re-­‐‑challenged  with  
doxorubicin  (1  µμg/ml)  for  3h.  Fresh  medium  was  added  after  chemotherapy  removal.  
DNA  damage  at  sequential  time  points  after  chemotherapy  treatment  was  analyzed  by  
neutral  comet  assay.  Representative  images  are  shown  at  each  time  point.  Cells  scored  as  
comet  tail-­‐‑positive  are  indicated  with  red  arrows  in  the  72  h  time  frame.  Right  panel:  
The  percent  cells  with  comet  tails  at  the  indicated  time  points  was  quantified  with  a  
fluorescence  microscope  using  Gen5  image  analysis  software  (BioTek,  VT).  Error  bars  
represent  S.D.,  n=3  fields  (each  contains  >50  cells).  Significance  of  data  points  at  24,  48  
and  72  h  was  determined  relative  to  data  reported  at  0  h  for  the  indicated  cell  population  
(*p<0.05,  **p<0.01,  ***p<0.001,  two-­‐‑tailed  student’s  t-­‐‑test).  .  Cells  scored  as  comet  tail-­‐‑
positive  are  indicated  with  red  arrows  in  the  72  h  time  frame.  Note  that  DNA  damage  
was  restored  to  baseline  at  72  h  post  Dox  rechallenge  for  dormant  cells,  but  not  for  
parental  cells.  B.  Left  panel:  BT549  dormant  cells  and  parental  (untreated)  cells  were  re-­‐‑
challenged  with  doxorubicin  (0.5  µμg/mL)  for  4  h.  DNA  damage  was  assessed  at  the  
indicated  times  using  the  neutral  comet  assay  as  in  “A”.  Right  panel:  The  percent  cells  
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with  comet  tails  at  the  indicated  time  points  was  quantified  as  in  “A”.  Cells  scored  as  
comet  tail-­‐‑positive  are  indicated  with  red  arrows  in  the  72  h  time  frame.  Note  that  DNA  
damage  was  restored  to  baseline  at  72  h  post  Dox  rechallenge  for  dormant  cells,  but  not  
for  parental  cells.  
  
4.2.9 Chemotherapy-enriched dormant tumor cells exhibit increased 
DNA-PK expression/activity 
DNA-­‐‑dependent  protein  kinase  (DNA-­‐‑PK)  is  the  key  functional  protein  
responsible  for  non-­‐‑homologous  end  joining  (NHEJ)  of  DNA  double  strand  breaks  
(DSB).  Previous  studies  using  bFGF  overexpression  models  suggest  that  nuclear  bFGF  
drives  DNA-­‐‑PKcs  transcription[30].  To  determine  whether  DNA-­‐‑PK  activation  is  
involved  in  TNBC  dormancy  in  our  in  vitro  model,  we  determined  the  expression  of  
DNA-­‐‑PKcs  in  chemotherapy-­‐‑enriched  dormant  tumor  cells.  Dormant  TN  tumor  cells  
expressed  increased  levels  of  both  DNA-­‐‑PKCS  and  phospho-­‐‑  Ser-­‐‑2056  DNA-­‐‑PK,  
representing  the  activated  form  of  DNA-­‐‑PK[27]  (Fig.  17).  
  
  
Figure  17:  Dormant  tumor  cells  have  increased  expression/phosphorylation  of  DNA-­‐‑
dependent  protein  kinase  (DNA-­‐‑PKcs)[40].  Left  and  middle  panel:  SUM159  cells  (Left  
panel)  and  BT549  cells  (Middle  panel)  were  treated  with  doxorubicin  as  described  in  Fig.  
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1A.  Nuclear  protein  from  parental  and  dormant  cells  was  extracted.  Equivalent  amounts  
were  immunoblotted  with  phopho  (Ser  2056)-­‐‑DNA-­‐‑PKCS  and  DNA-­‐‑PKCS  antibody.  
Protein  loading  was  assessed  using  Lamin  A  antibody.  Right  panel:  Protein  bands  from  
three  independent  trials  (SUM159  cells  treated  with  doxorubicin  as  described  in  Fig.  1A)  
were  quantified  using  Image  J  software  (NIH),  and  the  relative  ratio  of  DNA-­‐‑PKCS  to  
loading  control  is  shown  for  each  line.  Error  bars  represent  S.D.,  n=3,  **p<0.01,  two-­‐‑
tailed  student’s  t-­‐‑test.  
 
4.2.10 Chemotherapy-enriched dormant tumor cells exhibit increased 
DNA-PK mRNA level 
We  next  investigated  DNA-­‐‑PKcs  mRNA  levels  in  parental  and  dormant  SUM159  
cells  by  performing  quantitative  RT-­‐‑PCR.  Chemotherapy-­‐‑enriched  dormant  cells  
exhibited  increased  DNA-­‐‑PKcs  mRNA  expression  compared  to  parental  tumor  cells  
(Fig.  18).  Further  studies  are  needed  to  determine  whether  the  difference  in  mRNA  level  
is  caused  by  changes  in  transcriptional  regulation  or  mRNA  stability.    
                      
Figure  18:  Dormant  tumor  cells  exhibit  increased  DNA-­‐‑PK  mRNA  [40].  SUM159  cells  
were  treated  with  doxorubicin  as  described  in  Fig.  3.  Total  RNA  from  parental  and  
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PCR,  and  is  shown  as  fold  increase  to  β-­‐‑actin.  Error  bars  represent  S.D.,  n=3,  *p<0.05,  
two-­‐‑tailed  student’s  t-­‐‑test.  
           
4.2.11 bFGF regulates DNA-PK expression/activity in chemotherapy-
enriched dormant tumor cells  
Overexpression  of  bFGF  in  HeLa  cells  drives  the  expression  and  activation  of  
DNA-­‐‑PK  catalytic  subunit  (DNA-­‐‑PKCS)  [30].  To  determine  whether  nuclear  bFGF  
regulates  DNA-­‐‑PK  signaling  in  TNBC  dormancy  in  our  in  vitro  model,  we  determined  
the  expression  of  DNA-­‐‑PKcs  in  dormant  bFGF  knockdown  cells.  bFGF  knockdown  
significantly  decreased  the  DNA-­‐‑PKCS    protein  level  in  chemotherapy-­‐‑enriched  dormant  
tumor  cells,  indicating  an  upstream  regulation  of  DNA-­‐‑PKcs  by  bFGF  (Fig  19).  
  
  
Figure  19:  bFGF  knockdown  decreases  the  expression  of  DNA-­‐‑dependent  protein  
kinase  (DNA-­‐‑PKcs)  in  dormant  tumor  cells[40].  SUM159  or  BT549  cells  transfected  
with  bFGF  shRNA  or  control  shRNA  were  treated  with  doxorubicin  as  described  in  Fig.  
1A.  Nuclear  protein  from  dormant  cells  was  extracted.  Equivalent  amounts  were  
immunoblotted  with  DNA-­‐‑PKCS  antibody.  Protein  loading  was  accessed  using  Lamin  A  
antibody.  Protein  bands  were  quantified  using  Image  J  software  (NIH),  and  the  relative  
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4.2.12 bFGF knockdown in TN breast tumor cells decreases DNA 
double strand break (DSB) repair 
To  further  confirm  bFGF  regulation  of  DNA  repair,  we  examined  the  recovery  
after  short  term  chemotherapy  in  bFGF  or  control  shRNA  transfectants  by  neutral  comet  
assay.  Twenty-­‐‑four  hours  after  doxorubicin  challenge,  cells  expressing  a  bFGF  shRNA  
showed  a  similar  level  of  DNA  damage  to  that  of  cells  expressing  a  control  shRNA,  with  
approximately  70%  of  cells  having  a  comet  tail  (Fig.  20).  However,  control  shRNA-­‐‑
expressing  cells  exhibited  more  rapid  DNA  repair  than  bFGF  shRNA  transfectants,  with  
only  approximately  30%  control  shRNA-­‐‑expressing  cells  having  comet  tails  at  48  h  post  
challenge  (compared  to  approximately  60%  of  bFGF  shRNA-­‐‑expressing  cells  having  
comet  tails  at  this  time)  (Fig.  20).  Collectively,  these  results  suggest  that  chemotherapy-­‐‑
enriched  TN  dormant  tumor  cells  support  a  bFGF/DNA-­‐‑PK  signaling  axis  that  confers  
accelerated  DNA  double  strand  break  (DSB)  repair  capability,  allowing  them  to  survive  
chemotherapy  challenge  and  establish  recurrent  tumors.  
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Figure  20:  bFGF  knockdown  reduces  DNA  repair  capability  in  TN  breast  tumor  
cells[40].  Upper  panel:  BT549  cells  transfected  with  bFGF  shRNA  or  control  shRNA  
were  challenged  with  doxorubicin  (0.25  µμg/ml)  for  2  h.  Fresh  medium  was  added  after  
chemotherapy  removal.  DNA  damage  at  sequential  time  points  after  chemotherapy  
treatment  was  analyzed  by  neutral  comet  assay.  Representative  images  are  shown  for  
each  time  point.  Cells  scored  as  comet  tail-­‐‑positive  are  indicated  with  red  arrows  in  the  
48  h  time  frame.  Lower  panel:  The  percentages  of  cells  with  comet  tails  at  indicated  time  
points  were  quantified  with  a  fluorescence  microscope  using  Gen5  image  analysis  
software  (BioTek,  VT).  Error  bars  represent  S.D.,  n=3  fields  (each  field  containing  >50  
cells).  Significance  of  data  points  at  24  and  48  h  was  determined  relative  to  data  reported  
at  0  h  for  the  indicated  cell  population  (*p<0.05,  **p<0.01,  ***p<0.001,  two-­‐‑tailed  student’s  
t-­‐‑test).  Note  that  by  48  h,  the  percentage  of  cells  with  DNA  damage  was  significantly  
reduced  for  control  shRNA  cells,  but  not  for  bFGF  shRNA  cells.    
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4.2.13 Inhibition of DNA double strand break (DSB) repair by a 
selective DNA-PK inhibitor decreases the survival of chemo-residual 
dormant TN tumor cells 
NU7441  is  a  specific  inhibitor  of  DNA-­‐‑PK  with  100-­‐‑fold  selectivity  for  DNA-­‐‑PK  
compared  to  other  PI3K  kinase  family  members[26,  59].  To  determine  whether  DNA-­‐‑PK  
inhibition  can  reduce  TN  dormant  tumor  cell  survival  and  regrowth,  we  simultaneously  
treated  SUM159  TN  breast  tumor  cells  with  doxorubicin  and  NU7441  at  either  of  two  
non-­‐‑cytotoxic  concentrations[26].  NU7441  significantly  decreased  the  number  of  
doxorubicin-­‐‑enriched  dormant  cells  compared  to  DMSO  control  (Fig.  21).  
                               
Figure  21:  Selective  DNA-­‐‑PK  inhibitor  (NU7441)  reduces  dormant  tumor  cell  
survival[40].  SUM159  cells  were  treated  with  doxorubicin  (1  µμg/ml)  plus  DMSO  or  a  
selective  DNA-­‐‑PK  inhibitor  (NU7441),  at  non-­‐‑cytotoxic  concentration[26]  (1  µμM  or  5  
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Upper  panel:  Pictures  of  remaining  dormant  cells  were  taken  on  d7.  Magnification  40X.  
Lower  panel:  The  numbers  of  dormant  cells  on  d7  were  determined  by  trypan  blue  
exclusion.  Error  bars  represent  S.D.,  n=3,  *p<0.05,  **p<0.01,  two-­‐‑tailed  student’s  t-­‐‑test.  
  
4.2.14 Inhibition of DNA double strand break (DSB) repair by a 
selective DNA-PK inhibitor decreases recurrent colony formation 
Likewise,  treating  SUM159  cells  with  doxorubicin  and  NU7441  at  either  of  two  
non-­‐‑cytotoxic  concentrations  significantly  decreased  the  number  of  recurrent  colonies  
compared  to  DMSO  control  (Fig.  22).  Collectively,  these  results  suggest  that  DNA-­‐‑PK  
inhibition  by  NU7441  in  combination  with  chemotherapy  can  be  a  potential  strategy  to  
eliminate  chemo-­‐‑residual  dormant  TN  tumor  cells  and  block  tumor  recurrence.  
  
Figure  22:  Selective  DNA-­‐‑PK  inhibitor  (NU7441)  blocks  TN  breast  cancer  cell  
recurrent  colony  formation[40].  SUM159  cells  were  treated  with  doxorubicin  (1  µμg/ml)  
plus  DMSO  or  a  selective  DNA-­‐‑PK  inhibitor  (NU7441),  at  non-­‐‑cytotoxic  
concentration[26]  (1  µμM  or  5  µμM)  for  2  d,  as  described  in  Fig.  1A.  Fresh  medium  was  
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on  d  14,  16,  18,  respectively.  Error  bars  represent  S.D.,  n=3.  Significance  was  determined  
relative  to  DMSO  treated  cells  at  each  time  point  using  two-­‐‑tailed  student’s  t-­‐‑test  
(*p<0.05,  ***p<0.001).  Similar  results  were  obtained  in  at  least  three  independent  trials.  
  
4.2.15 bFGF expression in tumor samples from TNBC patients is 
associated with a higher recurrence rate 
We  examined  an  association  between  bFGF  mRNA  expression  and  tumor  
recurrence  status  in  TNBC  patients  using  the  Oncomine  cancer  gene  expression  
database.  We  found  30  datasets  containing  information  on  bFGF  expression  in  TNBC,  
but  only  1  of  the  30  datasets  reported  recurrence  status[36].  In  this  subset,  patients  who  
showed  recurrence  within  5  years  of  chemotherapy  treatment  had  significantly  higher  
bFGF  mRNA  expression  in  their  tumors  than  patients  without  recurrence  at  5  years  (Fig.  
23;  p=0.03  calculated  by  Mann-­‐‑Whitney  U  test).  This  finding  suggests  that  bFGF  
expression  in  primary  TN  breast  cancers  is  associated  with  increased  risk  of  tumor  
recurrence.  
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Figure  23:  Upregulated  bFGF  expression  in  tumor  samples  from  TNBC  patients  is  
associated  with  a  higher  recurrence  rate  after  neoadjuvant  chemotherapy  [40].  We  
tested  for  a  correlation  between  bFGF  mRNA  expression  and  tumor  recurrence  status  in  
TNBC  patients  using  the  Oncomine  cancer  gene  expression  database.  This  I-­‐‑SPY  1  
Trial[36]  was  the  only  one  which  met  our  selection  criteria,  providing  data  on  tumor  
recurrence.  TNBC  patients  (n=19)  received  neoadjuvant  chemotherapy  (mRNA  from  
tumor  samples  obtained  prior  to  patient  treatment  were  harvested  for  microarray  
analysis.  bFGF  expression  in  tumors  from  patients  prior  to  treatment  was  compared  
between  patients  without  recurrence  and  patients  with  recurrence  after  5  years.  Data  
were  presented  in  a  Box  and  whisker  plot.  The  boxes  span  the  interquartile  range.  The  
line  within  each  box  indicates  the  median.  The  ends  indicate  the  90th  and  the  10th  
percentile,  and  the  dots  represent  the  maximum  and  minimum  outlier  values.  The  
number  of  patients  without  recurrence  was  6,  the  number  of  patients  with  recurrence  
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4.3 Discussion 
While  cytosolic  (secreted)  bFGF  has  been  implicated  in  tumor  cell  therapy  
resistance[18-­‐‑23],  functions  for  nuclear  bFGF  isoforms  in  breast  cancer  have  not  been  
identified.  Our  work  is  the  first  to  implicate  nuclear  bFGF  in  TN  breast  cancer  
chemotherapy  resistance/tumor  recurrence.  The  data  suggest  that  nuclear  bFGF  drives  
resistance  to  anthracycline  chemotherapy,  an  activity  that  is  associated  with  nuclear  
bFGF  regulation  of  DNA-­‐‑PKcs  expression/DNA  repair.  
Previous  studies  indicate  that  tumor  resistance  to  anti-­‐‑angiogenic  therapy  is  
associated  with  increased  expression  of  cytosolic  FGF,  which  is  able  to  restore  tumor  
angiogenesis[18-­‐‑23].  Accordingly,  we  were  surprised  to  observe  upregulation  of  nuclear  
bFGF  isoforms,  but  not  cytosolic  bFGF  isoforms,  in  chemotherapy-­‐‑enriched  dormant  TN  
tumor  cells.  Our  studies  suggest  that  nuclear  bFGF  may  drive  TN  breast  cancer  
resistance  in  a  manner  independent  of  angiogenesis,  a  topic  of  future  investigation.    
We  observed  that  chemotherapy-­‐‑enriched  dormant  cells,  relative  to  parental  
SUM159  tumor  cells,  express  increased  levels  of  both  the  22  kDa  and  the  24  kDa  nuclear  
isoforms  of  bFGF  (Fig.  10).  In  order  to  determine  whether  both  nuclear  bFGF  isoforms  
are  critical  to  our  model,  we  performed  addback  studies  using  a  23  kDa  rat  nuclear  
bFGF  construct  (exhibiting  82%  homology  with  human  24  kDa  nuclear  bFGF).  This  23  
kDa  bFGF  isoform  alone  was  able  to  restore  recurrent  colony  formation  in  SUM159  cells  
expressing  a  bFGF  shRNA.    
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Expression  of  nuclear  vs  cytosolic  bFGF  isoforms  is  determined  by  alternative  
translation  pathways.  Whereas  cytosolic  bFGF  isoforms  are  regulated  by  CAP-­‐‑
dependent  translation,  nuclear  bFGF  isoforms  are  regulated  by  CAP-­‐‑independent  
translation.  Notably,  we  observed  increased  protein  levels  of  nuclear  but  not  cytosolic  
bFGF  isoforms  in  chemotherapy-­‐‑enriched  dormant  tumor  cells.  Our  data  suggests  that  
chemo-­‐‑residual  TN  tumor  cells  may  support  CAP-­‐‑independent  translation,  driving  
expression  of  nuclear  bFGF/DNA  repair.  We  are  currently  addressing  this  important  
hypothesis.  Ultimately,  it  may  be  possible  to  eliminate  these  chemo-­‐‑residual  dormant  
tumor  cells  by  targeting  the  CAP-­‐‑independent  translation  pathway.  
We  also  observed  that  bFGF  RNA  levels  are  increased  in  chemo-­‐‑residual  
dormant  TN  tumor  cells  relative  to  parental  tumor  cells  (Fig.  9).  Identifying  signaling  
pathways  that  drive  bFGF  transcription/mRNA  stability  in  chemotherapy-­‐‑enriched  
dormant  cells  has  the  potential  to  identify  rational  methods  for  targeting  these  chemo-­‐‑
residual  tumor  cells.  Of  note,  previous  studies  indicate  that  hypoxia  drives  bFGF  
transcription  in  a  hypoxia-­‐‑inducible  factor-­‐‑1  (HIF-­‐‑1)-­‐‑dependent  manner[60].  However,  
we  did  not  see  HIF-­‐‑1  expression  elevated  in  chemotherapy-­‐‑enriched  dormant  cells  (data  
not  shown),  suggesting  an  alternative  driver  of  bFGF  mRNA  expression  in  chemo-­‐‑
residual  tumor  cells.  
Our  work  identifies  DNA-­‐‑PKcs  as  a  downstream  target  of  nuclear  bFGF  in  
chemo-­‐‑residual  dormant  TN  tumor  cells.  DNA-­‐‑PKcs  has  previously  been  implicated  in  
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therapy  resistance[29,  56,  57,  61].  Long  term  chemotherapy  selection  models  have  been  
shown  to  select  for  chemo-­‐‑resistant  tumor  cells  with  increased  DNA-­‐‑PKcs  
expression/activity[61,  62].  The  current  study  is  unique  in  identifying  a  nuclear  growth  
factor  (nuclear  bFGF)  in  chemo-­‐‑residual  tumor  cells  that  drives  DNA-­‐‑PKcs  expression.  
Based  on  the  previous  demonstration  that  nuclear  bFGF  over-­‐‑expression  drives  DNA-­‐‑
PKcs  transcription[51],  we  are  currently  addressing  the  hypothesis  that  nuclear  bFGF  in  
chemo-­‐‑residual  TN  tumor  cells  drives  DNA-­‐‑PKcs  transcription.  
We  also  show  that  a  small  molecule  inhibitor  of  DNA-­‐‑PKcs  reduces  both  the  
number  of  chemo-­‐‑residual,  dormant  tumor  cells  (Fig.  21)  and  the  number  of  recurrent  
colonies  (Fig.  22)  in  our  in  vitro  model  of  TNBC  recurrence.  This  activity  may  be  
attributed  to  multiple  reported  activities  of  DNA-­‐‑PK.  This  DNA-­‐‑PKcs  inhibitor  likely  
reduces  the  number  of  chemo-­‐‑residual  dormant  tumor  cells  by  blocking  DNA  repair,  
leading  to  increased  tumor  cell  apoptosis.  However,  this  inhibitor  may  also  chemo-­‐‑
sensitize  TN  tumor  cells  by  inhibiting  a  recently  reported,  non-­‐‑conventional  activity  for  
DNA-­‐‑PK,  namely  its  ability  to  induce  AKT-­‐‑dependent  cell  survival[63].  Finally,  DNA-­‐‑
PK  is  a  critical  regulator  of  mitosis[64].  Thus  it  is  possible  that  inhibiting  DNA-­‐‑PK  in  our  
model  prevents  the  transition  of  chemo-­‐‑residual  dormant  tumor  cells  to  proliferative  
“recurrent”  tumor  cells.  
Nuclear-­‐‑localized  EGF  receptor  is  a  critical  determinant  of  DNA-­‐‑PK  activity[65].  
Based  on  this  knowledge,  in  addition  to  our  current  findings,  it  is  intriguing  to  speculate  
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that  nuclear  bFGF  may  control  DNA-­‐‑PKcs  expression/activity  in  a  manner  dependent  on  
a  nuclear  bFGF  receptor,  a  topic  of  current  investigation.  This  possibility  is  supported  by  
a  literature  demonstrating  that  nuclear  FGF  cooperates  with  a  nuclear  FGF  receptor  to  
drive  gene  transcription  in  neurons[66].  Identifying  a  bFGF  receptor  that  drives  nuclear  
bFGF/DNA-­‐‑PK  signaling  has  the  potential  to  define  a  logical  therapeutic  strategy  for  
eliminating  chemo-­‐‑residual  triple-­‐‑negative  breast  cancer  cells,  thus  preventing  tumor  
recurrence.  
   In  summary,  using  an  in  vitro  model,  we  demonstrate  a  critical  role  for  nuclear  
bFGF  in  TNBC  chemotherapy  resistance/tumor  recurrence.  To  begin  to  determine  the  
relevance  of  these  findings  in  the  clinic,  we  also  analyzed  gene  expression  profiles  of  
triple-­‐‑negative  breast  cancer  patients.  Notably,  we  found  that  bFGF  expression  in  
primary  TN  breast  cancers  is  associated  with  tumor  recurrence  (Fig.  23).  Future  studies  
are  needed  to  determine  which  bFGF  isoforms  (nuclear  or  cytosolic)  are  associated  with  
tumor  recurrence  in  TN  breast  cancer  patients.  Based  on  our  demonstration  that  
chemotherapy  enriches  for  bFGF-­‐‑expressing  tumor  cells  in  vitro,  it  will  also  be  important  
to  examine  frequency  of  bFGF  protein  expression  in  residual  tumor  cells  from  
neoadjuvant  chemotherapy-­‐‑treated  TN  breast  cancer  patients.
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5. “Recurrent” tumor cells evolving from in vitro model 
of TN Breast Cancer dormancy/ recurrence exhibit 
increased therapy resistance/invasive behavior 
5.1 Introduction 
Tumor  recurrence  is  the  principle  cause  of  death  in  TN  breast  cancer  patients.  In  
the  clinical  setting,  after  the  diagnosis  of  TN  breast  cancer,  patients  often  receive  
neoadjuvant  chemotherapy  treatment,  followed  by  surgical  intervention  and  adjuvant  
chemotherapy.  Although  achieving  high  rates  of  pathologic  complete  response  (pCR),  
TN  breast  cancer  patients  have  high  rates  of  local  or  distal  tumor  recurrence.  The  
recurrent  tumors  are  often  refractory  to  different  classes  of  chemotherapy  and  are  
usually  lethal  to  the  patients[3,  67,  68].    
Using  short  term  chemotherapy  to  resemble  clinical  neoadjuvant  chemotherapy,  
we  have  developed  an  in  vitro  model  of  tumor  recurrence  as  described  above  in  section  
3.  In  this  model,  about  two  weeks  after  chemotherapy  removal,  chemotherapy-­‐‑enriched  
dormant  tumor  cells  resume  growth  and  establish  “recurrent”  colonies  that  consist  of  
proliferating  cells.  These  proliferating  “recurrent”  cells  exhibit  resistance  to  the  original  
chemotherapy  as  well  as  cross-­‐‑resistance  to  a  different  class  of  chemotherapy.  Moreover,  
they  show  increased  DNA  repair  capacity  and  DNA-­‐‑PK  expression/activity  that  protect  
cells  from  DNA-­‐‑damaging  chemotherapeutic  agents.  Furthermore,  recurrent  tumor  cells  
demonstrate  accelerated  migration  and  invasion  ability.  Such  features  are  consistent  
with  the  aggressive  biological  behavior  of  recurrent  tumors  in  TN  breast  cancer  patients.  
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Thus,  the  characterization  of  recurrent  tumor  cells  in  our  in  vitro  model  and  the  
exploration  of  the  underlying  mechanisms  may  provide  potential  targets  for  developing  
effective  therapies  against  TN  breast  cancer  recurrence.    
  
5.2 Results 
5.2.1 Recurrent tumor cells are more resistant to chemotherapy than 
parental tumor cells 
Recurrent  tumors  are  frequently  detected  in  cancer  patients  many  years  after  
initial  chemotherapy  treatment,  and  these  tumors  are  chemo-­‐‑refractory[69].  Similar  to  
recurrent  tumors  in  patients,  recurrent  tumor  cells  evolving  in  our  model  from  
chemotherapy-­‐‑enriched  dormant  cells  exhibited  increased  chemotherapy  resistance  (Fig.  
24).  Increased  therapy  resistance  was  observed  in  two-­‐‑independent  recurrent  breast  
tumor  cell  lines  (Rec-­‐‑511  and  Rec-­‐‑817tx).  Notably,  resistant  recurrent  breast  tumor  
colonies  were  observed  independent  of  the  class  of  chemotherapy  treatment  (taxane  vs  
anthracycline)  (Fig.  24).  
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Figure  24:  Tumor  cells  from  recurrent  colonies  are  more  resistant  to  chemotherapy  
than  parental  tumor  cells[41].  A.  Left  panel:  SUM159  breast  tumor  cells  were  incubated  
with  doxorubicin  as  in  Fig.  3.  Residual  tumor  cells  were  allowed  to  grow  in  the  absence  
of  chemotherapy,  resulting  in  the  evolution  of  “recurrent”  colonies.  Tumor  cells  from  
recurrent  colonies    (Rec-­‐‑511),  as  well  as  parental  tumor  cells,  were  re-­‐‑challenged  with  the  
indicated  concentrations  of  doxorubicin.  Chemo-­‐‑sensitivity  was  assessed  by  [3H]-­‐‑
thymidine  incorporation.  Data  for  each  point  are  expressed  as  fold  change  relative  to  
cells  cultured  in  medium  only.  Right  panel:  IC50  was  calculated  using  linear  regression  
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panel:  SUM159  breast  tumor  cells  were  incubated  with  docetaxel  as  in  Fig.  4.  Residual  
tumor  cells  were  allowed  to  grow  in  the  absence  of  chemotherapy,  resulting  in  the  
evolution  of  “recurrent”  colonies.  Tumor  cells  from  recurrent  colonies  (Rec-­‐‑817tx)  and  
parental  tumor  cells  were  re-­‐‑challenged  with  the  indicated  concentrations  of  docetaxel.  
Chemo-­‐‑sensitivity  was  assessed  by  thymidine  incorporation,  as  in  A.  Right  panel:  IC50  
was  calculated  using  linear  regression  analysis.  Error  bars  represent  S.D.,  n=3,  **p<0.01,  
two-­‐‑tailed  student’s  t-­‐‑test.  
  
5.2.2 Recurrent tumor cells have cross-resistance to different class of 
chemotherapy  
To  determine  whether  recurrent  tumor  cells  evolving  in  our  model  from  
chemotherapy-­‐‑enriched  dormant  cells  exhibited  cross-­‐‑resistance  to  different  classes  of  
chemotherapy,  we  treated  doxorubicin-­‐‑resistant  recurrent  tumor  cells  (Rec-­‐‑1217)  with  
docetaxel,  and  docetaxel-­‐‑resistant  recurrent  tumor  cells  (Rec-­‐‑817tx)  with  doxorubicin.  
Both  recurrent  cell  lines  exhibit  cross-­‐‑resistance  to  different  chemotherapy  class,  
compared  to  untreated  parental  tumor  cells  (Fig.  25).    
  
  




Figure  25:  Recurrent  tumor  cells  have  cross-­‐‑resistance  to  different  class  of  
chemotherapy.  A.  Left  panel:  SUM159  breast  tumor  cells  were  incubated  with  
doxorubicin  as  in  Fig.  3.  Residual  tumor  cells  were  allowed  to  grow  in  the  absence  of  
chemotherapy,  resulting  in  the  evolution  of  “recurrent”  colonies.  Tumor  cells  from  
recurrent  colonies  (Rec-­‐‑511),  as  well  as  parental  tumor  cells,  were  challenged  with  the  
indicated  concentrations  of  docetaxel.  Chemo-­‐‑sensitivity  was  assessed  by  thymidine  
incorporation.  Data  for  each  point  are  expressed  as  fold  change  relative  to  cells  cultured  
in  medium  only.  Error  bars  represent  S.D.,  n=3,  **p<0.01,  two-­‐‑tailed  student’s  t-­‐‑test.  
Right  panel:  IC50  was  calculated  using  linear  regression  analysis.  B.  Left  panel:  
SUM159  breast  tumor  cells  were  incubated  with  docetaxel  as  in  Fig.  4.  Residual  tumor  
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“recurrent”  colonies.  Tumor  cells  from  recurrent  colonies  (Rec-­‐‑817tx)  and  parental  
tumor  cells  were  challenged  with  the  indicated  concentrations  of  doxorubicin.  Chemo-­‐‑
sensitivity  was  assessed  by  thymidine  incorporation,  as  in  A.  Right  panel:  IC50  was  
calculated  using  linear  regression  analysis.  Error  bars  represent  S.D.,  n=3,  **p<0.01,  two-­‐‑
tailed  student’s  t-­‐‑test.  
 
5.2.3 Recurrent tumor cells exhibit accelerated DNA double strand 
break (DSB) repair 
We  showed  in  section  4.2.8  that  chemotherapy-­‐‑enriched  dormant  tumor  cells  
exhibit  accelerated  DNA  double  strand  break  repair.  To  examine  the  DNA  double  strand  
break  (DSB)  repair  capability  in  recurrent  tumor  cells,  we  re-­‐‑challenged  the  untreated  
parental  cells  and  recurrent  tumor  cells  with  doxorubicin  (DNA  damaging  agent)  for  3  h  
and  examined  their  recovery  by  neutral  comet  assay.  As  shown  in  Fig.  26,  the  percentage  
of  cells  with  comet  tails  returned  to  baseline  faster  in  recurrent  cells  than  in  parental  cells.  
This  data  indicates  that  recurrent  tumor  cells  repaired  DNA  double  strand  breaks  more  
quickly  than  parental  cells,  which  contributes  to  chemoresistance.  
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Figure  26:  Recurrent  tumor  cells  exhibit  accelerated  DNA  double  strand  break  repair.  
SUM159  were  treated  with  doxorubicin  as  described  in  Fig.  3.  Residual  tumor  cells  were  
allowed  to  grow  in  the  absence  of  chemotherapy,  resulting  in  the  evolution  of  
“recurrent”  colonies.  Upper  panel:  recurrent  cells  and  parental  (untreated)  cells  were  re-­‐‑
challenged  with  doxorubicin  (1  µμg/ml)  for  3h.  Fresh  medium  was  added  after  
chemotherapy  removal.  DNA  damage  at  sequential  time  points  after  chemotherapy  
treatment  was  analyzed  by  neutral  comet  assay.  Representative  images  are  shown  at  
each  time  point.  Lower  panel:  The  percent  cells  with  comet  tails  at  the  indicated  time  
points  was  quantified  with  a  fluorescence  microscope  using  Gen5  image  analysis  
software  (BioTek,  VT).  Error  bars  represent  S.D.,  n=3  fields  (each  contains  >50  cells).  
Significance  of  data  points  at  24,  48  and  72  h  was  determined  relative  to  data  reported  at  
0  h  for  the  indicated  cell  population  (*p<0.05,  **p<0.01,  ***p<0.001,  two-­‐‑tailed  student’s  t-­‐‑
test).  Note  that  DNA  damage  was  significantly  reduced  at  48  h  and  72  h  post  
doxorubicin  rechallenge  for  recurrent  cells,  but  not  for  parental  cells.  
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5.2.4 Recurrent tumor cells demonstrate increased DNA-PK 
expression/ activity 
We  showed  in  section  4.2.9  that  chemotherapy-­‐‑enriched  dormant  tumor  cells  
exhibit  increased  expression/activation  of  DNA-­‐‑PK.  To  determine  whether  DNA-­‐‑PK  
activation  is  involved  in  chemoresistance  of  recurrent  tumor  cells,  we  determined  the  
expression  of  DNA-­‐‑PKcs  in  recurrent  tumor  cells  evolving  from  chemotherapy-­‐‑enriched  
dormant  cells.  Recurrent  tumor  cells  expressed  increased  levels  of  both  DNA-­‐‑PKCS  and  
phospho-­‐‑  Ser-­‐‑2056  DNA-­‐‑PK,  representing  the  activated  form  of  DNA-­‐‑PK[27]  (Fig.  27).  
Notably,  Histone  H2A.X  (DNA  damage  marker)  phosphorylation  is  decreased  in  
recurrent  cells,  indicating  accelerated  DNA  damage  repair.  
  
  
Figure  27:  Recurrent  tumor  cells  have  increased  expression/phosphorylation  of  DNA-­‐‑
dependent  protein  kinase  (DNA-­‐‑PKcs).  SUM159  were  treated  with  doxorubicin  as  
described  in  Fig.  3.  Residual  tumor  cells  were  allowed  to  grow  in  the  absence  of  
chemotherapy,  resulting  in  the  evolution  of  “recurrent”  colonies.  Nuclear  protein  from  
parental  and  recurrent  cells  was  extracted.  Equivalent  amounts  were  immunoblotted  
with  phopho  (Ser  2056)-­‐‑DNA-­‐‑PKCS,  DNA-­‐‑PKCS,  and  phospho-­‐‑H2A.X  antibody.  Protein  
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loading  was  assessed  using  Lamin  A  antibody.  Similar  results  were  obtained  in  at  least  
three  independent  trials.  
 
5.2.5 Recurrent tumor cells exhibit decreased proliferation compared 
to parental tumor cells 
To  further  characterize  the  difference  in  biological  properties  between  recurrent  
and  parental  tumor  cells,  we  determined  their  proliferation  rate  by  [3H]-­‐‑thymidine  
uptake  assay.  We  observed  significantly  decreased  growth  rate  in  recurrent  tumor  cells  
compared  to  untreated  parental  cells,  regardless  of  the  chemotherapy  class  studied  
(doxorubicin  or  docetaxel,  Fig.  28).  
  
  
A                                                              B 
       
Figure  28:  Recurrent  tumor  cells  exhibit  decreased  proliferation.  A.  SUM159  breast  
tumor  cells  were  incubated  with  doxorubicin  as  in  Fig.  3.  Residual  tumor  cells  were  
allowed  to  grow  in  the  absence  of  chemotherapy,  resulting  in  the  evolution  of  
“recurrent”  colonies.  Tumor  cells  from  recurrent  colonies  (Rec-­‐‑511)  as  well  as  untreated  
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thymidine  incorporation  (+/-­‐‑SD).  B.  SUM159  breast  tumor  cells  were  incubated  with  
docetaxel  as  in  Fig.  4.  Residual  tumor  cells  were  allowed  to  grow  in  the  absence  of  
chemotherapy,  resulting  in  the  evolution  of  “recurrent”  colonies.  Tumor  cells  from  
recurrent  colonies  (Rec-­‐‑817tx)  as  well  as  untreated  parental  tumor  cells  were  plated  to  
96-­‐‑well  plate.  Proliferation  was  determined  by  [3H]-­‐‑thymidine  incorporation  (+/-­‐‑SD).  
n=4,  ***p<0.001,  two-­‐‑tailed  student’s  t-­‐‑test.  
  
5.2.6 Recurrent tumor cells exhibit increased migration in vitro 
Recurrent  breast  tumors  are  frequently  found  in  distal  organs  including  lungs,  
bones,  brain,  and  liver.  Such  metastasis  is  associated  with  increased  migration  and  
invasion  ability  of  recurrent  tumor  cells[35].  To  determine  whether  the  recurrent  tumor  
cells  evolving  in  our  model  from  chemotherapy-­‐‑enriched  dormant  cells  exhibited  
increased  migratory  capacity,  we  performed  a  wound-­‐‑healing  migration  assay.  
Recurrent  tumor  cells  demonstrated  accelerated  wound  closure  compared  to  untreated  
parental  cells,  indicating  increased  migratory  capacity  (Fig.  29).  
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Figure  29:  Recurrent  tumor  cells  exhibit  increased  migration  in  vitro.  SUM159  breast  
tumor  cells  were  incubated  with  doxorubicin  as  in  Fig.  3.  Residual  tumor  cells  were  
allowed  to  grow  in  the  absence  of  chemotherapy,  resulting  in  the  evolution  of  
“recurrent”  colonies.  Tumor  cells  from  recurrent  colonies,  as  well  as  parental  tumor  
cells,  were  plated  on  a  24-­‐‑well  plate  and  grew  to  reach  confluence.  Cells  in  the  middle  of  
each  well  were  mechanically  scratched  using  a  pipette  tip.  Cell  debris  were  removed  by  
PBS  wash.  Fresh  medium  was  added.  Images  were  taken  on  0  h  and  8  h.  At  least  three  
random  locations  were  examined  and  representative  pictures  were  shown.    
  
5.2.7 Recurrent tumor cells demonstrate increased invasiveness in 
vitro 
To  determine  whether  the  recurrent  tumor  cells  evolving  in  our  model  from  
chemotherapy-­‐‑enriched  dormant  cells  exhibited  increased  invasiveness,  we  performed  a  
transwell  invasion  assay.  Recurrent  tumor  cells  migrated  through  matrigel  faster  than  
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untreated  parental  cells,  indicating  increased  invasiveness  and  metastatic  potential  (Fig.  
30).  
                
Figure  30:  Recurrent  tumor  cells  exhibit  increased  invasiveness  in  vitro.  SUM159  
breast  tumor  cells  were  incubated  with  docetaxel  as  in  Fig.  4.  Residual  tumor  cells  were  
allowed  to  grow  in  the  absence  of  chemotherapy,  resulting  in  the  evolution  of  
“recurrent”  colonies.  Tumor  cells  from  recurrent  colonies,  as  well  as  parental  tumor  
cells,  were  serum-­‐‑starved  for  24  h.  Equal  amounts  of  cells  were  added  to  the  upper  
chambers  of  a  matrigel-­‐‑coated  plate.  Complete  medium  was  added  to  the  bottom  
chambers.  After  12  h,  cells  that  migrated  into  the  bottom  chambers  were  fixed  and  
stained  with  crystal  violet.  The  number  of  migrated  cells  was  counted  from  three  fields  
under  microscope.  Error  bars  represent  S.D.,  n=3,  ***p<0.001,  two-­‐‑tailed  student’s  t-­‐‑test.  
5.2.8 Recurrent tumor cells exhibit increased expression of tumor 
migration and invasion markers 
To  explore  the  underlying  mechanisms  of  increased  migration  and  invasiveness  
in  recurrent  tumor  cells,  we  examined  the  expression  of  protein  markers  associated  with  
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associated  with  invasive  breast  carcinoma.  MMP-­‐‑2  belongs  to  the  matrix  
metalloproteinase  family  and  is  responsible  for  disrupting  basement  membrane  and  
facilitating  cancer  cell  migration  and  metastasis[70,  71].  The  recurrent  tumor  cells  
evolving  in  our  model  from  chemotherapy-­‐‑enriched  dormant  cells  expressed  increased  
levels  of  phospho-­‐‑c-­‐‑Jun  and  MMP-­‐‑2  compared  to  untreated  parental  tumor  cells  (Fig.  
31),  consistent  with  increased  migration  and  invasiveness  observed  in  wound-­‐‑healing  
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Figure  31:  Recurrent  tumor  cells  exhibit  increased  expression/activation  of  c-­‐‑Jun  and  
MMP-­‐‑2.  SUM159  breast  tumor  cells  were  incubated  with  docetaxel  as  in  Fig.  4.  Residual  
tumor  cells  were  allowed  to  grow  in  the  absence  of  chemotherapy,  resulting  in  the  
evolution  of  “recurrent”  colonies.  Total  cellular  protein  was  extracted  from  parental,  
dormant,  and  recurrent  SUM159  cells,  and  equivalent  amounts  were  immunoblotted  
with  indicated  antibodies,  followed  by  IrDye-­‐‑conjugated  secondary  antibody.  Protein  
loading  was  assessed  using  Actin  or  Lamin  A  antibodies.    
  
5.2.9 Recurrent tumor cells exhibit advanced Epithelial-mesenchymal 
transition (EMT)  
Epithelial-­‐‑mesenchymal  transition  (EMT)  is  a  critical  step  for  cancer  migration,  
invasion,  and  metastasis.  It  is  associated  with  loss  of  epithelial  protein  markers,  such  as  
pan-­‐‑cytokeratin,  and  with  gain  of  mesenchymal  protein  markers,  such  as  N-­‐‑cadherin[34,  
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72].  We  compared  the  expression  of  EMT  protein  markers  between  parental  and  
recurrent  tumor  cells  in  our  in  vitro  model.  SUM159  cell  line  has  undergone  EMT.  
However,  the  recurrent  cells  expressed  higher  N-­‐‑cadherin  and  lower  pan-­‐‑cytokeratin  
than  parental  cells,  indicating  an  advanced  stage  of  EMT,  predicting  increased  
invasiveness  and  metastatic  potential  (Fig.  32).  
  
  
Figure  32:  Recurrent  tumor  cells  exhibit  increased  expression  of  N-­‐‑cadherin  and  
decreased  expression  of  pan-­‐‑cytokeratin.  SUM159  breast  tumor  cells  were  incubated  
with  docetaxel  as  in  Fig.  4.  Residual  tumor  cells  were  allowed  to  grow  in  the  absence  of  
chemotherapy,  resulting  in  the  evolution  of  “recurrent”  colonies.  Total  cellular  protein  
was  extracted  from  parental  and  recurrent  cells,  and  equivalent  amounts  were  
immunoblotted  with  indicated  antibodies,  followed  by  IrDye-­‐‑conjugated  secondary  
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5.3 Discussion 
Our  study  focused  on  the  ability  of  the  TN  dormant  tumor  cells  in  our  short-­‐‑term  
chemotherapy  treatment  model  to  resume  growth  and  establish  “recurrent”  colonies  
upon  chemotherapy  withdrawal,  resembling  the  process  of  tumor  recurrence.  Notably,  
recurrent  tumor  cells  evolving  after  chemotherapy  withdrawal  were  more  resistant  to  
subsequent  chemotherapy  challenge  than  parental  tumor  cells.  Recurrent  cells  were  
resistant  both  to  the  original  chemotherapy  class,  as  well  as  to  other  chemotherapy  
classes,  indicating  broad  chemoresistance  across  different  regimens.  The  therapy  
resistance  of  recurrent  tumor  cells  in  our  model  resembles  expanded  therapy  resistance  
of  recurrent  tumors  in  cancer  patients[73].  Such  resistance  of  recurrent  cells  to  DNA-­‐‑
damaging  agent  (doxorubicin)  can  be  explained  by  their  increased  expression/activation  
of  DNA-­‐‑PK  and  elevated  DNA  repair  capacity.  Studies  have  shown  that  microtubule-­‐‑
modulating  agent  (Paclitaxel)  causes  DNA  damage  in  cancer  cells  by  increasing  reactive  
oxygen  species  (ROS)[74].  Therefore,  the  increased  DNA  repair  ability  in  recurrent  cells  
evolving  after  doxorubicin  treatment  may  explain  their  cross-­‐‑resistance  to  docetaxel.  
However,  the  specific  type  of  DNA  damage  (double  strand  break  vs.  single  strand  
break)  caused  by  taxanes  remains  to  be  clarified,  and  further  studies  (DNA-­‐‑PK  
knockdown,  selective  DNA-­‐‑PK  inhibitor)  are  needed  to  confirm  the  exact  role  of  DNA-­‐‑
PK  in  cross-­‐‑resistance  to  therapy.  To  date,  we  haven’t  examined  the  expression  of  DNA-­‐‑
PK  in  recurrent  cells  evolving  from  docetaxel  treatment.  Whether  they  possess  the  same  
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mechanism  of  chemoresistance  as  recurrent  cells  evolving  from  doxorubicin  remains  to  
be  elucidated.  Additionally,  we  observed  decreased  proliferation  in  recurrent  tumor  
cells.  This  alteration  may  also  contribute  to  their  resistance  as  most  chemotherapeutic  
agents  target  fast  proliferating  cells[75].    
The  resistant  phenotype  of  recurrent  tumor  cells  evolving  from  our  
chemotherapy-­‐‑enriched  dormant  cells  contrasts  with  the  reversible-­‐‑resistant  phenotype  
of  tumor  cells  subjected  to  long-­‐‑term  drug  selection[38,  47].  We  have  observed  
continued  resistance  of  our  “recurrent”  breast  tumor  lines  at  least  50  days  after  
chemotherapy  withdrawal  (representing  approximately  40  doubling  times  for  these  
cells;  data  not  shown).  The  irreversible  resistance  of  these  drug  resistant  tumor  cells  has  
important  implications  for  patient  treatment.  Specifically,  the  existence  of  irreversible  
drug  resistant  phenotypes  in  the  original  tumor  argues  against  models  suggesting  that  
recurrent  tumors  arising  in  patients  after  a  gap  in  treatment  (“drug  holiday”)  may  
benefit  from  retreatment  with  the  same  therapy[73].  Studies  are  ongoing  to  determine  if  
“recurrent”  tumor  cells  from  our  in  vitro  model  remain  chemo-­‐‑refractory  for  months  
after  therapy  withdrawal.  
Moreover,  recurrent  tumor  cells  exhibit  more  aggressive  behaviors  compared  to  
parental  tumor  cells,  as  demonstrated  by  increased  migration,  invasion,  and  EMT.  
Increased  aggressive  behaviors  of  recurrent  cells  (compared  to  parental  cells)  are  
supported  by  expression  levels  of  molecular  markers  of  these  behaviors  (e.g.  N-­‐‑cadherin,  
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MMP-­‐‑2).  Studies  are  ongoing  to  identify  signaling  pathways  that  can  be  used  as  
potential  targets  for  developing  novel  therapies  that  can  prevent  recurrent  tumor  
growth.    
Many  studies  suggest  that  tumor  cells  disseminated  to  distal  organs  undergo  
mesenchymal-­‐‑epithelial  transition  (MET)  before  establishing  recurrent  tumors[72,  76,  
77].  Surprisingly,  we  observed  advanced  EMT  in  recurrent  cells  in  our  model.  One  
explanation  is  that  the  “recurrent”  cells  in  our  model  do  not  represent  the  metastatic  
recurrent  tumor  cells  in  patients.  Instead,  they  are  more  similar  to  the  mobilizing,  
invasive,  and  mesenchymal-­‐‑like  tumor  cells  that  escape  into  blood  circulation.  This  
similarity  is  supported  by  recent  studies  that  the  presence  of  circulating  tumor  cells  
(CTCs)  predicts  metastatic  recurrence  and  survival  in  breast  cancer  patients,  and  CTCs  
in  patients  with  metastatic  breast  cancer  express  both  epithelial  and  mesenchymal  
molecular  markers[78-­‐‑80].  Accordingly,  it  remains  possible  that  our  in  vitro  tumor  
recurrence  model  resembles  an  early  stage  of  tumor  metastasis/recurrence.  Specifically,  
chemoresistant  dormant  tumor  cells  remain  quiescent  during  chemotherapy  onslaught,  
but  resume  proliferation  during  interval  between  chemotherapy  cycles  (“drug  
holidays”),  resulting  in  producing  highly  aggressive  tumor  cells  (“recurrent”  cells  in  our  
model)  that  later  go  through  the  invasion-­‐‑metastasis  cascade.  Notably,  our  preliminary  
in  vivo  experiments  show  that  after  entering  blood  circulation  through  tail  vein  injection  
in  mice,  the  recurrent  cells  from  our  in  vitro  model  develop  lung  and  bone  colonization  
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faster  and  larger  than  untreated  parental  tumor  cells,  indicating  elevated  extravasation  
capacity  and  invasiveness.  Studies  are  ongoing  to  examine  whether  the  tumor  cells  in  
established  lung/bone  nodules  undergo  MET.  Additionally,  future  studies  are  needed  to  
examine  the  expression  of  nuclear  bFGF/DNA-­‐‑PK  in  CTC  isolated  from  blood  of  TN  
breast  cancer  patients.
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6. Concluding Remarks and Future Directions 
6.1 Summary of findings 
The  first  portion  of  our  studies  focused  on  establishing  in  vitro  models  of  TN  
breast  cancer  dormancy/recurrence.  Using  short  term  chemotherapy  treatment  to  enrich  
for  drug-­‐‑resistant  tumor  cells,  we  have  developed  an  in  vitro  model  of  tumor  recurrence.  
In  this  model,  short-­‐‑term  exposure  of  TN  breast  tumor  cells  to  clinical-­‐‑relevant  
chemotherapy  classes/doses  enriches  for  a  population  of  slow-­‐‑cycling  (dormant)  tumor  
cells.  Chemotherapy-­‐‑enriched  dormant  tumor  cells  resume  proliferation  after  
chemotherapy  withdrawal,  forming  colonies  resembling  a  tumor  recurrence.    
Next,  we  identified  nuclear  bFGF/DNA-­‐‑PKcs  as  a  key  signaling  pathway  driving  
TN  breast  cancer  dormancy/recurrence  (Fig.  33).  We  observed  upregulation  of  nuclear  
bFGF  isoforms,  but  not  cytosolic  bFGF  isoforms,  in  chemotherapy-­‐‑enriched  dormant  TN  
tumor  cells.  Nuclear  bFGF  is  necessary  and  sufficient  to  drive  the  survival  of  dormant  
tumor  cells  and  establishment  of  recurrent  colonies  as  confirmed  by  bFGF  knockdown  
and  add  back  studies.  Additionally,  we  identified  DNA-­‐‑PKcs  as  a  downstream  target  of  
nuclear  bFGF  in  chemo-­‐‑residual  dormant  TN  tumor  cells.  A  small  molecule  inhibitor  of  
DNA-­‐‑PKcs  reduces  both  the  number  of  chemo-­‐‑residual,  dormant  tumor  cells  and  the  
number  of  recurrent  colonies  in  our  in  vitro  model  of  TN  breast  cancer  recurrence.  This  
DNA-­‐‑PKcs  inhibitor  likely  reduces  the  number  of  chemo-­‐‑residual  dormant  tumor  cells  
by  blocking  DNA  repair,  leading  to  increased  tumor  cell  apoptosis.  Moreover,  we  also  
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analyzed  gene  expression  profiles  of  triple-­‐‑negative  breast  cancer  patients.  Notably,  we  
found  that  bFGF  expression  in  primary  TN  breast  cancers  is  associated  with  tumor  
recurrence.    
           
Figure  33:  Model  of  tumor  recurrence  mechanism.  Chemotherapy-­‐‑enriched  dormant  
TN  tumor  cells  have  increased  nuclear  bFGF  expression.  Nuclear  bFGF  upregulates  
DNA-­‐‑PK  expression  and  activation.  Increased  DNA-­‐‑PK  activity  accelerates  DNA  repair.  
The  completion  of  DNA  repair  initiates  cell  regrowth,  resulting  in  tumor  recurrence.  
  
Finally,  we  characterized  the  properties  of  recurrent  tumor  cells  evolving  after  
chemotherapy  withdrawal  in  our  model.  Recurrent  cells  were  more  resistant  to  
subsequent  chemotherapy  challenge  than  parental  tumor  cells,  and  showed  broad  
chemoresistance  to  different  regimens.  Such  resistance  in  recurrent  tumor  cells  is  likely  
associated  with  their  increased  expression/activation  of  DNA-­‐‑PK  and  elevated  DNA  
repair  capacity.  We  also  showed  that  recurrent  tumor  cells  demonstrate  increased  
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migration,  invasion,  and  EMT,  implying  an  aggressive  behavior  consistent  with  
recurrent  tumor  in  TN  breast  cancer  patients.    
Chemotherapy  has  been  the  only  systemic  treatment  of  TN  breast  cancer  for  a  
long  time.  However,  our  studies  suggest  that  chemotherapy  alone  may  accelerate  
disease  progression  by  enriching  for  a  chemo-­‐‑resistant  sub-­‐‑population  that  can  form  
recurrent  tumor  with  aggressive  behavior  and  expanded  therapy  resistance.  Thus,  
developing  combination  therapy  targeting  both  chemo-­‐‑sensitive  and  chemo-­‐‑resistant  
tumor  cells  is  essential  for  eradication  of  TN  breast  cancer.  
6.2 Future studies 
To  further  improve  our  in  vitro  model  of  tumor  recurrence,  we  will  determine  
whether  other  chemotherapies  (cisplatin,  cyclophosphamide)  or  sequential  therapy  
combining  different  regimens  also  enrich  dormant  cells  that  subsequently  lead  to  
recurrence.  It  is  important  to  determine  whether  dormant  and  recurrent  tumor  cells  
treated  with  different  therapies  share  common  molecular  markers.  Specifically,  gene  
expression  profiles  will  be  obtained  from  different  dormant  and  recurrent  cells  and  we  
will  seek  to  identify  genes  with  similar  expression  changes  as  potential  future  
therapeutic  targets.  
After  developing  a  TN  breast  cancer  dormancy/recurrence  model  and  
elucidating  the  underlying  mechanism  in  vitro,  the  next  step  is  to  test  it  in  vivo  using  an  
orthotopic  mouse  model.  Specifically,  we  plan  to  inject  TN  breast  cancer  cells  into  the  
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mammary  fat  pad  of  female  athymic  nude  mice.  Doxorubicin  will  be  injected  IV  after  the  
establishment  of  palpable  tumor.  When  significant  shrinkage  of  tumor  is  achieved,  the  
residual  tumor  will  be  extracted.  Dormancy  status  (p21  expression)  and  bFGF  
expression  will  be  examined  in  residual  tumor  cells.    According  to  our  in  vitro  studies,  
we  expect  to  see  increased  level  of  p21  and  bFGF  in  residual  tumor  cells.  Furthermore,  
we  will  confirm  the  function  of  nuclear  bFGF  in  tumor  dormancy/recurrence  in  this  
orthotopic  mouse  model.  Specifically,  we  plan  to  inject  TN  breast  cancer  cells  expressing  
nuclear  bFGF  shRNA  +/-­‐‑  23  kDa  bFGF  vector  or  control  shRNA  +/-­‐‑  23  kDa  bFGF  vector  
into  the  mammary  fat  pad  of  female  athymic  nude  mice.  Doxorubicin  will  be  injected  IV  
after  after  the  establishment  of  palpable  tumor.  The  dose  of  doxorubicin  will  be  carefully  
determined  to  reduce  tumor  volume,  but  will  not  eliminate  tumor  cells[81],  providing  a  
window  for  studying  additive  effects  of  doxorubicin  +  bFGF  knockdown.  Tumor  volume  
will  be  measured  with  a  caliper  3x/wk.  When  complete  tumor  disappearance  is  achieved,  
mice  will  be  followed  for  tumor  recurrence.  Time  to  recurrence  will  be  calculated  using  
Kaplan  Meier  survival  analysis.  
Expression  of  nuclear  vs  cytosolic  bFGF  isoforms  is  determined  by  alternative  
translation  pathways.  Whereas  cytosolic  bFGF  isoforms  are  regulated  by  CAP-­‐‑
dependent  translation,  nuclear  bFGF  isoforms  are  regulated  by  CAP-­‐‑independent  
translation.  Notably,  we  observed  increased  protein  levels  of  nuclear  but  not  cytosolic  
bFGF  isoforms  in  chemotherapy-­‐‑enriched  dormant  tumor  cells.  Our  data  suggests  that  
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chemo-­‐‑residual  TN  tumor  cells  may  support  CAP-­‐‑independent  translation,  driving  
expression  of  nuclear  bFGF/DNA  repair.  We  are  currently  addressing  this  important  
hypothesis.  Ultimately,  it  may  be  possible  to  eliminate  these  chemo-­‐‑residual  dormant  
tumor  cells  by  targeting  the  CAP-­‐‑independent  translation  pathway.  
Based  on  our  demonstration  that  chemotherapy  enriches  for  bFGF-­‐‑expressing  
tumor  cells  in  vitro,  it  will  also  be  important  to  examine  frequency  of  bFGF  protein  
expression  in  residual  tumor  cells  from  neoadjuvant  chemotherapy-­‐‑treated  TN  breast  
cancer  patients.  Based  on  our  finding  that  bFGF  expression  in  primary  TN  breast  cancers  
is  associated  with  tumor  recurrence,  future  studies  are  needed  to  determine  which  bFGF  
isoforms  (nuclear  or  cytosolic)  are  associated  with  tumor  recurrence  and  predicts  
prognosis  in  TN  breast  cancer  patients.  
To  date,  it  is  unclear  that  whether  dormant  cells  enriched  by  different  
chemotherapy  agents  (doxorubicin  or  docetaxel)  are  from  the  same  sub-­‐‑population,  
although  they  have  similar  properties  such  as  upregulated  nuclear  bFGF.  It  is  also  
important  to  identify  unique  molecular  markers  that  can  be  used  to  isolate  chemo-­‐‑
resistant  dormant  cells  from  the  original  population.  We  plan  to  perform  bFGF  staining  
on  untreated  TN  breast  cancer  cell  lines  as  well  as  on  untreated  patient  tumor  biopsy  
samples  to  address  whether  bFGF  can  be  used  as  a  molecular  marker  to  identify  
dormant  tumor  cells.  
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Nuclear-­‐‑localized  EGF  receptor  is  a  critical  determinant  of  DNA-­‐‑PK  activity[65].  
Based  on  this  knowledge,  in  addition  to  our  current  findings,  it  is  intriguing  to  speculate  
that  nuclear  bFGF  may  control  DNA-­‐‑PKcs  expression/activity  in  a  manner  dependent  on  
a  nuclear  bFGF  receptor,  a  topic  of  current  investigation.  This  possibility  is  supported  by  
a  literature  demonstrating  that  nuclear  FGF  cooperates  with  a  nuclear  FGF  receptor  to  
drive  gene  transcription  in  neurons[66].  Identifying  a  bFGF  receptor  that  drives  nuclear  
bFGF/DNA-­‐‑PK  signaling  has  the  potential  to  define  a  logical  therapeutic  strategy  for  
eliminating  chemo-­‐‑residual  triple-­‐‑negative  breast  cancer  cells,  thus  preventing  tumor  
recurrence.    
Previously  studies  show  that  nuclear  bFGF  over-­‐‑expression  drives  DNA-­‐‑PKcs  
transcription[30].  We  will  address  the  hypothesis  that  nuclear  bFGF  in  chemo-­‐‑residual  
TN  tumor  cells  drives  DNA-­‐‑PKcs  transcription.  Specifically,  we  will  measure  DNA-­‐‑PKcs  
transcription  in  control  shRNA-­‐‑expressing  cells  and  bFGF  shRNA-­‐‑expressing  cells  by  
luciferase  gene  reporter  assay.  
As  mentioned  above  in  section  1.4,  BRCA  mutation  is  frequently  associated  with  
TN  breast  cancer  and  increases  tumor  cell  susceptibility  to  DNA-­‐‑damaging  agents[2].  
However,  the  cell  lines  used  in  our  studies  (SUM159,  BT549)  have  wild  type  BRCA1[82].  
Future  studies  are  needed  to  examine  the  effect  of  blocking  DNA-­‐‑PK  activity  in  BRCA1  
mutated  TN  breast  cancer  cell  lines  (SUM149,  SUM1315,  and  HCC1937)  because  
dormant  cells  in  these  cell  lines  are  probably  more  vulnerable  to  DNA-­‐‑PK  activity  
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inhibition  due  to  lack  of  an  alternative  DNA  repair  pathway  (homologous  
recombination  by  BRCA1).  Therefore,  combination  therapy  (chemotherapy  +  DNA-­‐‑PK  
inhibitor)  may  achieve  increased  efficacy  in  TN  breast  cancer  patients  carrying  BRCA1  
mutation.  Accordingly,  BRCA  mutation  can  be  a  promising  molecular  marker  to  justify  
the  use  of  a  DNA-­‐‑PK  inhibitor  added  to  conventional  chemotherapy  for  treating  TN  
breast  cancer  patients.  
Additional  studies  will  pursue  understanding  the  mechanisms  of  
chemoresistance  and  invasiveness  in  recurrent  tumor  cells.  Based  on  our  demonstration  
that  nuclear  bFGF  promotes  the  survival  of  dormant  cells  after  chemotherapy  and  the  
importance  of  nuclear  bFGF  during  development  of  metastasis[25],  we  will  assess  the  
role  of  nuclear  bFGF  on  chemoresistance  and  invasiveness  in  recurrent  cells  in  our  
model.  siRNA  targeting  nuclear  bFGF  will  be  transfected  into  recurrent  cells  to  achieve  
transient  nuclear  bFGF  knockdown.  Chemotherapy  sensitivity  will  be  evaluated  by  
thymidine  uptake  and  clonogenic  assay.  Invasiveness  will  be  assessed  by  transwell  
invasion  assay.  
In  our  model,  dormant  cells  and  recurrent  cells  have  many  different  properties  
(morphology,  growth  rate,  migration,  and  invasiveness).  Mechanisms  underlying  the  
conversion  from  dormant  cells  to  recurrent  cells  are  still  unknown.  Alterations  in  
pathways  regulating  cell  cycle  (Cyclin-­‐‑dependent  kinases)  and  pathways  promoting  
EMT  (Snail,  Twist,  or  TGFβ)  need  to  be  characterized  in  the  transition  of  dormant  cells  to  
    87  
proliferative  recurrent  cells.    These  studies  will  provide  novel  approaches  to:  1)  block  
dormant  tumor  cells  reentry  into  cell  cycle  to  prevent  local  recurrence;  and  2)  inhibit  the  
transition  into  “more  aggressive”  recurrent  cells  with  increased  migratory  and  invasive  
behavior  to  prevent  distal  metastasis  in  TN  breast  cancer  patients. 
6.3 Conclusion 
We  developed  an  in  vitro  model  of  TN  breast  cancer  dormancy/recurrence.  Short-­‐‑
term  exposure  of  tumor  cells  to  chemotherapy  at  clinically  relevant  doses  enriches  for  a  
dormant  tumor  cell  population  that  can  regain  proliferative  ability  and  establish  
recurrent  colonies,  resembling  tumor  recurrence.  Furthermore,  we  identified  a  novel  
signaling  axis  (nuclear  bFGF/DNA-­‐‑PK)  that  drives  accelerated  DNA  repair  in  
chemotherapy-­‐‑enriched  dormant  TN  breast  cancer  cells.  Targeting  this  axis  with  either  a  
bFGF  shRNA  or  DNA-­‐‑PK  small  molecule  inhibitor  blocks  recurrent  colony  formation.  
We  found  that  bFGF  expression  in  tumor  samples  from  TN  breast  cancer  patients  
predicts  five-­‐‑year  tumor  recurrence  following  neoadjuvant  chemotherapy  treatment.  
Additionally,  we  demonstrated  that  recurrent  tumor  cells  exhibit  increased  
chemotherapy  resistance  and  invasiveness,  resembling  therapy  resistance  of  recurrent  
tumors  in  patients.  Collectively,  our  studies  on  the  mechanisms  underlying  TN  breast  
cancer  dormancy/recurrence  provide  a  novel  therapeutic  strategy  for  TN  breast  cancer  
treatment.  
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